View Filing Data

Document And Entity Information - USD ($)	12 Months Ended
Oct. 31, 2014	Dec. 26, 2014	Apr. 30, 2014
Document And Entity Information
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Document Type	10-K
Document Period End Date	Oct. 31, 2014
Amendment Flag	false
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Current Reporting Status	Yes
Current Fiscal Year End Date	--10-31
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 50,339,157
Entity Common Stock, Shares Outstanding		23,644,808
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

Balance Sheets - USD ($)	Oct. 31, 2014	Oct. 31, 2013
Current Assets:
Cash	$ 17,606,860	$ 20,552,062
Prepaid Expenses	182,978	31,255
Income Tax Receivable	1,731,317
Other Current Assets	8,182	8,182
Deferred Expenses - current	964,724	218,007
Total Current Assets	20,494,061	20,809,506
Deferred Expenses - long-term		129,041
Property and Equipment (net of accumulated depreciation)	77,369	80,385
Intangible Assets (net of accumulated amortization)	2,767,945	2,528,551
Other Assets	38,438	38,438
TOTAL ASSETS	23,377,813	23,585,921
Current Liabilities:
Accounts Payable	1,411,058	3,841,771
Accrued Expenses	1,241,796	869,260
Short-term Convertible Notes and Fair Value of Embedded Derivative	62,882	62,882
Notes Payable - Officer (including interest payable)		163,132
Total Current Liabilities	2,715,736	4,937,045
Common Stock Warrant Liability	32,091	646,734
Total Liabilities	2,747,827	5,583,779
Commitments and Contingencies
Shareholders' Equity:
Preferred Stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; issued and outstanding 0 at October 31, 2014 and 2013. Liquidation preference of $0 at October 31, 2014 and 2013.
Common Stock - $0.001 par value; authorized 45,000,000 shares, issued and outstanding 19,630,139 at October 31, 2014 and 13,719,861 at October 31, 2013.	19,630	13,720
Additional Paid-In Capital	107,601,493	88,454,245
Accumulated Deficit	(86,991,137)	(70,465,823)
Total Shareholders' Equity	20,629,986	18,002,142
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	$ 23,377,813	$ 23,585,921

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Oct. 31, 2014	Oct. 31, 2013
Income Statement [Abstract]
Revenue	$ 1,000,000
Research and Development Expenses	8,687,168	5,621,989
General and Administrative Expenses	11,851,410	9,071,613
Total Operating expenses	20,538,578	14,693,602
Loss from Operations	(19,538,578)	(14,693,602)
Other Income (expense):
Interest Expense	(5,253)	(987,746)
Other Income (Expense)	36,305	(70,876)
Gain (Loss) on Note Retirement	6,243	(3,455,327)
Gain (Loss) on Change in Fair Value of Common Stock Warrant Liability and Embedded Derivative Liability	619,089	(1,504,465)
Net Loss before Income tax Benefit	(18,882,194)	(20,712,016)
Income Tax Benefit	2,356,880	725,190
Net Loss	(16,525,314)	(19,986,826)
Dividends Attributable to Preferred Shares		555,000
Net Loss applicable to Common Stock	$ (16,525,314)	$ (20,541,826)
Net Loss per Common Share, Basic and Diluted	$ (.97)	$ (4.10)
Weighted average number of common shares outstanding, basic and diluted	17,106,577	5,012,105

Statements of Shareholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Promissory Note And Interest Receivable [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Oct. 31, 2012		$ 3,158	$ (10,484,022)	$ 52,119,567	$ (47,601,427)	$ (5,962,724)
Balance, shares at Oct. 31, 2012	740	3,158,419
Stock compensation to employees, directors and consultants				2,855,183		2,855,183
Issuance of shares upon conversion of convertible promissory notes		$ 1,286		5,763,660		5,764,946
Issuance of shares upon conversion of convertible promissory notes, shares		1,285,706
Common Stock issued upon exercise of warrants		$ 494		2,308,006		2,308,500
Common Stock issued upon exercise of warrants, shares		493,675
Common Stock issued to consultants		$ 393		1,690,809		1,691,202
Common Stock issued to consultants, shares		393,459
Issuance of shares to employees under ESPP Plan		$ 6		28,034		28,040
Issuance of shares to employees under ESPP Plan, shares		6,334
Issuance of shares to investorsunder stock purchase agreements		$ 37		127,214		127,251
Issuance of shares to investorsunder stock purchase agreements, shares		36,888
Interest On Optimums Notes Receivable			(149,562)	149,562
Fractional shares cashed out		$ (2)		2
Fractional shares cashed out, shares		(1,604)
Issuance of shares under HanoverEquity Line		$ 387		3,120,902		3,121,290
Issuance of shares under HanoverEquity Line, shares		387,224
Issuance of shares under IronridgeSettlement		$ 267		934,643		934,910
Issuance of shares under IronridgeSettlement, shares		267,117
To record Beneficial ConversionFeature on convertible promissory notes				118,190		118,190
Notice of Redemption and SettlementAgreement with Optimus		$ 34	10,633,584	(7,756,048)	(2,877,570)
Notice of Redemption and SettlementAgreement with Optimus, shares	(740)	33,750
Issuance of shares to Socius		$ 5		24,902		24,907
Issuance of shares to Socius, shares		4,981
Brio Settlement		$ 22		232,348		232,370
Brio Settlement, shares		21,742
Issuance of earned but not issued shares to former employees		$ 71		(71)
Issuance of earned but not issued shares to former employees, shares		70,554
Partial conversion of Moore Notes		$ 41		150,449		150,490
Partial conversion of Moore Notes, shares		40,783
Issuance of shares under exchange agreement with Redwood		$ 125		699,875		700,000
Issuance of shares under exchange agreement with Redwood, shares		125,000
Issuance of shares under exchange agreement with Redwood		$ 783		2,803,549		2,804,332
Issuance of shares under exchange agreement with Redwood, shares		783,333
Advaxis Public Offering		$ 6,613		23,083,469		$ 23,090,081
Advaxis Public Offering, shares		6,612,500				6,334
Net Loss					(19,986,826)	$ (19,986,826)
Balance at Oct. 31, 2013		$ 13,720		88,454,245	(70,465,823)	18,002,142
Balance, shares at Oct. 31, 2013		13,719,861
Stock compensation to employees, directors and consultants		$ 502		2,879,777		2,880,279
Stock compensation to employees, directors and consultants, shares		501,651
Common Stock issued upon exercise of warrants				250		250
Common Stock issued upon exercise of warrants, shares		50
Common Stock issued to consultants		$ 247		1,551,186		1,551,433
Common Stock issued to consultants, shares		247,218
Issuance of shares to employees under ESPP Plan		$ 2		6,249		6,251
Issuance of shares to employees under ESPP Plan, shares		2,110
Issuance of shares to investorsunder stock purchase agreements		$ 467		2,033,670		2,034,137
Issuance of shares to investorsunder stock purchase agreements, shares		467,249
Advaxis Public Offering		$ 4,692		12,676,116		$ 12,680,808
Advaxis Public Offering, shares		4,692,000				2,110
Net Loss					(16,525,314)	$ (16,525,314)
Balance at Oct. 31, 2014		$ 19,630		$ 107,601,493	$ (86,991,137)	$ 20,629,986
Balance, shares at Oct. 31, 2014		19,630,139

Statement of Cash Flows - USD ($)	12 Months Ended
Statement of Cash Flows - USD ($)	Oct. 31, 2014	Oct. 31, 2013
OPERATING ACTIVITIES
Net Loss	$ (16,525,314)	$ (19,986,826)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash charges to consultants and employees for options and stock	4,428,712	4,545,992
Amortization of deferred financing costs		85,943
Amortization of discount on convertible promissory notes		18,392
Non-cash interest expense	51	845,200
(Gain) Loss on change in value of warrants and embedded derivative	(619,089)	1,504,465
Warrant expense	4,446	123,744
Settlement expense	34,125	764,335
Employee Stock Purchase Plan	6,251	28,055
Depreciation expense	27,611	19,299
Amortization expense of intangibles	175,686	159,337
(Gain) on note retirement	(6,243)	3,455,327
Change in operating assets and liabilities:
Prepaid expenses	(151,723)	(18,387)
Taxes receivable	(1,731,317)
Deferred expenses	(617,676)	855,252
Accounts payable and accrued expenses	(1,948,987)	(1,140,901)
Interest payable	(98,192)	31,631
Deferred rent		(4,803)
Net cash used in operating activities	(17,021,659)	(8,713,945)
INVESTING ACTIVITIES
Proceeds from sale of property and equipment		3,000
Purchase of property and equipment	(24,595)	(24,616)
Cost of intangible assets	(415,080)	(274,133)
Net cash used in Investing Activities	(439,675)	(295,749)
FINANCING ACTIVITIES
Proceeds from convertible notes		2,968,500
Repayment of convertible notes		(690,799)
Cash paid for deferred financing costs		(66,919)
Proceeds from Officer Loan		11,200
Repayment of Officer Loan	(64,926)	(193,833)
Proceeds from the exercise of warrants	250	94,444
Net proceeds of issuance of Common Stock	14,580,808	27,438,931
Net cash provided by Financing Activities	14,516,132	29,561,524
Net increase (decrease) in cash	(2,945,202)	20,551,830
Cash at beginning of year	20,552,062	232
Cash at end of year	17,606,860	20,552,062
Supplemental Disclosures of Cash Flow Information
Cash paid for Interest	103,445	125,988
Cash paid for Taxes
Supplemental Schedule of Noncash Investing and Financing Activities
Accounts Payable and Accrued Expenses settled with Common Stock	103,012
Accounts Payable from consultants settled with Common Stock		776,302
Notes payable and embedded derivative liabilities converted to Common Stock		4,646,148
Cancellation of Note Receivable in connection with Preferred Stock Redemption		(10,633,584)
Common Stock issued in exchange for warrants		$ 2,308,500

Summary of Significant Accounting Policies

12 Months Ended

Oct. 31, 2014

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Estimates

The preparation of financial statements in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ substantially from these estimates. Significant estimates include the fair value and recoverability of the carrying value of intangible assets (patents and licenses), the fair value of options, the fair value of embedded conversion features, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results may differ from estimates.

Reclassification

Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss.

Revenue Recognition

The Company derived the majority of its revenue in 2014 from patent licensing. In general, these revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. The intellectual property rights granted may be perpetual in nature, or upon the final milestones being met, or can be granted for a defined, relatively short period of time, with the licensee possessing the right to renew the agreement at the end of each contractual term for an additional minimum upfront payment. The Company recognizes licensing fees when there is persuasive evidence of a licensing arrangement, fees are fixed or determinable, delivery has occurred and collectability is reasonably assured.

An allowance for doubtful accounts is established based on the Company’s best estimate of the amount of probable credit losses in the Company’s existing license fee receivables, using historical experience. The Company reviews its allowance for doubtful accounts periodically. Past due accounts are reviewed individually for collectability.

Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. To date, this is yet to occur.

If product development is successful, the Company will recognize revenue from royalties based on licensees’ sales of its products or products using its technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. If royalties cannot be reasonably estimated or collectability of a royalty amount is not reasonably assured, royalties are recognized as revenue when the cash is received.

The Company recognizes revenue from milestone payments received under collaboration agreements when earned, provided that the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, the Company has no further performance obligations relating to the event and collection is reasonably assured. If these criteria are not met, the Company recognizes milestone payments ratably over the remaining period of the Company’s performance obligations under the collaboration agreement. All such recognized revenues are included in collaborative licensing and development revenue in the Company’s consolidated statements of operations.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of October 31, 2014 and October 31, 2013, the Company did not have any cash equivalents.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $17.6 million is subject to credit risk at October 31, 2014. However, these cash balances are maintained at creditworthy financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

Deferred Expenses

Deferred Expenses consistent of advanced payments made on research and development projects. Amortization is provided for on a straight-line basis over the periods of the underlying research and development contracts ranging from six months to five years and is charged to Research and Development Expense in the Statement of Operations.

Property and Equipment

Property and equipment consists of laboratory equipment and is stated at cost. Depreciation and amortization is provided for on the straight-line basis over the estimated useful lives of the respective asset ranging from 3 to 5 years. Expenditures for maintenance and repairs that do not materially extend the useful lives of the respective assets are charged to expense as incurred. The cost and accumulated depreciation of assets retired or sold are removed from the respective accounts and any gain or loss is recognized in operations.

Intangible Assets

Intangible assets primarily consist of legal and filing costs associated with obtaining patents and licenses and are amortized on a straight-line basis over their remaining useful lives which are estimated to be twenty years from the effective dates of the University of Pennsylvania (Penn) License Agreements, beginning in July 1, 2002. These legal and filing costs are invoiced to the Company through Penn and its patent attorneys.

Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable and its carrying amount exceeds its fair value, which is based upon estimated undiscounted future cash flows. Net assets are recorded on the balance sheet for patents and licenses related to ADXS-HPV, ADXS-PSA and ADXS-HER2 and other products that are in development. However, if a competitor were to gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, the Company would likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value.

Deferred Financing Costs

The Company has recorded deferred financing costs as a result of fees incurred by the Company in conjunction with its debt financing activities. These costs are amortized using the straight-line method over the shorter of (a) the term of the related debt or (b) the expected conversion date of the debt into equity instruments, which approximates the effective interest method. The amortization of deferred financing costs is included in interest expense as a component of other expenses in the accompanying statements of operations. For the year ended October 31, 2013, amortization of deferred financing costs was immaterial, and as of October 31, 2013, deferred financing costs were fully amortized.

Net Loss per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential Common Stock equivalents outstanding during the period. Therefore, in the case of a net loss the impact of the potential Common Stock resulting from warrants, outstanding stock options and convertible debt is not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income the impact of the potential Common Stock resulting from these instruments that have intrinsic value is included in the diluted earnings per share. The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share.

	As of October 31,
	2014		2013
Warrants		4,158,092		4,265,262
Stock Options		467,968		467,923
Convertible Debt (using the if-converted method)		3,354		3,354
Total		4,629,414		4,736,539

Research and Development Expenses

Research and development costs are expensed as incurred and include but are not limited to clinical trial and related manufacturing costs, payroll and personnel expenses, lab expenses, and related overhead costs.

Advertising Expense

Advertising costs are charged to operations as incurred. For the years ended October 31, 2014 and 2013 the Company did not incur any advertising costs.

Stock Based Compensation

The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally measured based on contractual terms. The fair value amount is then recognized over the requisite service period, usually the vesting period, in both research and development expenses and general and administrative expenses on the statement of operations depending on the nature of the services provided by the employees or consultants.

The process of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over their requisite service period involves significant assumptions and judgments. The Company estimates the fair value of stock option awards on the date of grant using the Black Scholes Model (“BSM”) for the remaining awards, which requires that the Company makes certain assumptions regarding: (i) the expected volatility in the market price of its Common Stock; (ii) dividend yield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise (referred to as the expected holding period). As a result, if the Company revises its assumptions and estimates, stock-based compensation expense could change materially for future grants.

The Company accounts for stock-based compensation using fair value recognition and record stock-based compensation as a charge to earnings net of the estimated impact of forfeited awards. As such, the Company recognizes stock-based compensation cost only for those stock-based awards that are estimated to ultimately vest over their requisite service period, based on the vesting provisions of the individual grants.

Fair Value of Financial Instruments

The carrying amounts of financial instruments, including cash, accounts payable and accrued expenses approximated fair value as of the balance sheet date presented, because of the relatively short maturity dates on these instruments. The carrying amounts of the financing arrangements issued approximate fair value as of the balance sheet date presented, because interest rates on these instruments approximate market interest rates after consideration of stated interest rates, anti-dilution protection and associated warrants.

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used the Black Scholes valuation model which approximated the binomial lattice options pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months of the balance sheet date.

Hybrid Financial Instruments

For certain hybrid financial instruments, the Company elected to apply the fair value option to account for these instruments. The Company made an irrevocable election to measure such hybrid financial instruments at fair value in their entirety, with changes in fair value recognized in earnings at each balance sheet date. The election may be made on an instrument by instrument basis.

Debt Discount and Amortization of Debt Discount

Debt discount represents the fair value of embedded conversion options of various convertible debt instruments and attached convertible equity instruments issued in connection with debt instruments. The debt discount is amortized over the earlier of (i) the term of the debt or (ii) conversion of the debt, using the straight-line method which approximates the effective interest method. The amortization of debt discount is included as interest expense as a component of other expenses in the accompanying statements of operations.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. Amendments in this ASU create Topic 606, Revenue from Contracts with Customers, and supersede the revenue recognition requirements in Topic 605, Revenue Recognition, including most industry-specific revenue recognition guidance throughout the Industry Topics of the Codification. In addition, the amendments supersede the cost guidance in Subtopic 605-35, Revenue Recognition—Construction-Type and Production-Type Contracts, and create new Subtopic 340-40, Other Assets and Deferred Costs—Contracts with Customers. In summary, the core principle of Topic 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU is the final version of Proposed ASU 2011-230—Revenue Recognition (Topic 605) and Proposed ASU 2011–250—Revenue Recognition (Topic 605): Codification Amendments, both of which have been deleted. The amendments in this ASU are effective for the Company for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating the effects of ASU 2014-09 on the consolidated financial statements.

In June 2014, the FASB issued ASU 2014-12, Compensation - Stock Compensation. The amendments in this ASU apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target can be achieved after the requisite service period. This ASU is the final version of Proposed ASU EITF-13D--Compensation--Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, which has been deleted. The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. As indicated in the definition of vest, the stated vesting period (which includes the period in which the performance target could be achieved) may differ from the requisite service period. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, and early adoption is permitted. The Company does not expect ASU 2014-12 to have a material impact on the consolidated financial statements.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying consolidated financial statements.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

Convertible Notes and Fair Value of Embedded Derivative

12 Months Ended

Oct. 31, 2014

Debt Disclosure [Abstract]

Convertible Notes and Fair Value of Embedded Derivative

6. CONVERTIBLE NOTES AND FAIR VALUE OF EMBEDDED DERIVATIVE

Junior Subordinated Convertible Promissory Notes

The Company refers to all Junior Subordinated Convertible Promissory Notes as “Bridge Notes”.

The Bridge Notes are convertible into shares of the Company’s Common Stock at a fixed exercise price. For every dollar invested in the Company’s Bridge Notes, each Investor received warrant coverage ranging from approximately 23% to 75%, subject to adjustments upon the occurrence of certain events as more particularly described below and in the form of Warrant. As of October 31, 2012, substantially all of the Bridge Warrants have an exercise price of $18.75 per share. The Bridge Notes may be prepaid in whole or in part at the option of the Company without penalty at any time prior to the Maturity Date. The warrants may be exercised on a cashless basis under certain circumstances.

During the twelve months ended October 31, 2013, pursuant to the terms of various Assignment Agreements, the Company delivered convertible notes to Magna in aggregate principal amounts of $170,589 (including $11,765 of junior subordinated convertible promissory notes plus the above December 2011 Note in the principal amount of $158,824) and $111,111 (consisting of one junior subordinated convertible promissory note), convertible into shares of Common Stock, which bears interest at a rate of 6% per annum, which interest accrues, but does not become payable until maturity. The Company converted the exchange note, which it refers to as the Third Magna Exchange Note, in the principal amount of $111,111 into 34,241 shares of its Common Stock at a conversion price of $3.25 per share, recording non-cash expense of approximately $106,000 to the loss on retirement account, on the statement of operations, for the difference between the amount of the principal converted and the fair value of the shares issued as a result of the conversion. As of October 31, 2013, approximately $63,000 in principal remained outstanding on the junior unsubordinated convertible promissory notes, as the notes had matured on October 22, 2011. As of October 31, 2014, these notes are recorded as current liabilities on the balance sheet. The Company is in discussion with note holders to convert these notes in full during fiscal year 2015.

JMJ Financial

On August 27, 2012, in a private placement pursuant to a Note Purchase Agreement, the Company issued JMJ Financial a convertible promissory note in the aggregate principal amount of $100,000 for a purchase price of $100,000, which it refers to as the JMJ August 2012 Note. As of October 31, 2012, the JMJ August 2012 Note remained outstanding. Due to the conversion feature into a variable number of shares, the JMJ August 2012 Note is valued at fair value at each reporting period. As of October 31, 2012, the fair value of the JMJ August 2012 Note was $73,590.

During the twelve months ended October 31, 2013, the Company converted the JMJ August 2012 Note totaling $100,000 into 24,744 shares of its Common Stock. The Company recorded non-cash income of approximately $70,114 upon conversion. This non-cash income was recorded to the gain on retirement account, on the statement of operations, representing the difference between the fair value of the JMJ August 2012 Note, as reported on the balance sheet, and the fair value of the shares issued as a result of the conversion.

On December 28, 2012, in a private placement pursuant to a note purchase agreement, the Company issued JMJ Financial a one month convertible promissory note, which it refers to as the JMJ December 2012 Note, in the aggregate principal amount of $100,000 for a purchase price of $100,000 . If repaid before January 31, 2013, the principal amount of the JMJ December 2012 Note would be $125,000. If the JMJ December 2012 Note was to be rolled into a future financing, the principal amount would be $115,000.

On April 26, 2013, in a private placement, the Company issued JMJ Financial a convertible promissory note (“JMJ April 2013 Note”). The face amount of the note reflects an aggregate principal amount of $800,000 for total consideration of $720,000 (or a 10 % original issue discount). As of April 26, 2013, the Company had only borrowed $425,000 from JMJ Financial under this convertible promissory note. JMJ Financial paid $300,000 in cash and exchanged the JMJ December 2012 Note with an aggregate principal amount of $125,000 as consideration for the note. The exchange was analyzed and management concluded that the exchange qualifies for modification accounting. On June 27, 2013, the Company borrowed an additional $100,000 under the convertible promissory note. JMJ Financial has no obligation to lend the Company the remaining $195,000 of available principal amount under the note and may never do so. The Company has no obligation to pay JMJ Financial any amounts on the unfunded portion of the note. The Company may not prepay any portion of the note without JMJ Financial’s consent.

The convertible promissory note matures April 26, 2014 and, in addition to the 10% original issue discount, provides for payment of a one-time interest charge of 5% on funded amounts. The convertible promissory note is convertible at any time, in whole or in part, at JMJ Financial’s option into shares of the Company’s Common Stock at the lesser of $8.75 or 70% of the average of the lowest two closing prices in the 20-day pricing period preceding a conversion. However, at no time will JMJ Financial be entitled to convert any portion of the note to the extent that after such conversion, JMJ Financial (together with its affiliates) would beneficially own more than 4.99% of the Company’s outstanding shares of Common Stock as of such date. The Company agreed to reserve at least 160,000 shares of its Common Stock for conversion of the note. The note also provides for penalties and rescission rights if the Company does not deliver shares of its Common Stock upon conversion within the required timeframes.

The convertible promissory note includes customary event of default provisions, and provides for a default rate of the lesser of 18 % or the maximum permitted by law. Upon the occurrence of an event of default, the lender may require the Company to pay in cash the “Mandatory Default Amount” which is defined in the note to mean the greater of (i) the outstanding principal amount of the note plus all interest, liquidated damages and other amounts owing under the note, divided by the conversion price on the date payment of such amount is demanded or paid in full, whichever is lower, multiplied by the volume-weighted-average price, or VWAP, on the date payment of such amount is demanded or paid in full, whichever has a higher VWAP, or (ii) 150% of the outstanding principal amount of the note plus 100% of all interest, liquidated damages and other amounts owing under the note.

The Company also granted JMJ Financial the right, at its election, to participate in the next public offering of its securities by exchanging, in whole or in part, the funded portion of this note for a subscription to such public offering in an amount equal to 125% of the sum of the funded portion of the principal amount being exchanged plus all accrued and unpaid interest, liquidated damages, fees, and other amounts due on such exchanged principal amount. However, the note was subsequently amended in September 2013 to remove this right. If the Company completes a public offering of $10,000,000 or more, JMJ Financial has the right, at its election, to require repayment of the note, in whole or in part, in amount equal to 125% of the sum of the funded principal amount being repaid plus all accrued and unpaid interest liquidated damages, fees, and other amounts due on such principal amount. In September 2013, this note was amended to lower this threshold to $5,000,000 in connection with the sale of the new convertible promissory note to JMJ Financial.

On August 14, 2013, the Company borrowed an additional $100,000 under the JMJ April 2013 convertible promissory note. At this date, the Company has borrowed 625,000 under the JMJ April 2013 Note. JMJ Financial has no obligation to lend the Company the remaining $95,000 of available principal amount under the note and may never do so. The Company has no obligation to pay JMJ Financial any amounts on the unfunded portion of the note and may not prepay any portion of the note without JMJ Financial’s consent. During August and September 2013, JMJ Financial converted $145,833 in principal and interest on its April 2013 Note into 71,438 shares of Common Stock at conversion rates ranging from $1.89 to $2.20. After these conversions, $583,333 in principal and interest remained outstanding under the JMJ April 2013 Note.

On September 4, 2013, in a private placement, the Company issued JMJ Financial a convertible promissory note (“JMJ September 2013 Note”). The face amount of the note reflects an aggregate principal amount of $800,000 for total consideration of $720,000 (or a 10% original issue discount). However, JMJ Financial has only paid us $500,000 in cash as consideration for the note to date. The Company also issued JMJ Financial 19,231 restricted shares of its Common Stock as a $50,000 origination fee for this convertible promissory note. JMJ Financial has no obligation to lend us the remaining $220,000 of available consideration under the note and may never do so. The convertible promissory note matures September 4, 2014 and, in addition to the 10% original issue discount, provides for payment of a one-time interest charge of 5% on funded amounts. The convertible promissory note is convertible at any time, in whole or in part, at JMJ Financial’s option into shares of the Company’s Common Stock at the lesser of $2.65 or 70% of the average of the lowest two closing prices in the 20-day pricing period preceding a conversion. However, at no time will JMJ Financial be entitled to convert any portion of the note to the extent that after such conversion, JMJ Financial (together with its affiliates) would beneficially own more than 4.99% of the Company’s outstanding shares Common Stock as of such date. The Company agreed to reserve at least 2,000,000 shares of the Company’s Common Stock for conversion of the note. $583,333 in principal and interest remained outstanding under the JMJ September 2013 Note.

As of October 16, 2013, the Company owed JMJ Financial approximately $ 1,167,000 in principal and interest under its convertible promissory notes with JMJ Financial. On October 16, 2013, the Company entered into an Accelerated Conversion and Note Termination Agreement with JMJ Financial whereby it agreed to exchange all of its outstanding convertible promissory notes (which had an aggregate principal amount of approximately $1,167,000), plus fees of approximately $400,000 (recorded as non-cash interest expense), for accelerated conversion, note termination and a lock-up, for an aggregate of 783,333 restricted shares of its Common Stock at an effective conversion price of $2.00. The Company recorded non-cash expense of approximately $922,000 upon conversion. This non-cash expense was recorded to the loss on retirement account, on the statement of operations representing the difference between the fair value of the JMT April and September Notes and the fair value of the shares issued as a result of the conversion. JMJ Financial also agreed to certain lock-up restrictions with respect to such shares. Accordingly, JMJ Financial agreed not to sell any of such shares until 60 days after the date of the agreement, following which, until 90 days after the date of the agreement, it agreed to limit the number of such shares it sells on any day to 10% of the trading volume on such day. JMJ Financial also agreed not to engage in any short sales of the Company’s Common Stock at any time.

At October 31, 2014, there were no remaining convertible promissory notes outstanding with JMJ Financial.

Hanover Holdings Notes

On September 19, 2012, in a private placement pursuant to a note purchase agreement, the Company issued Hanover a convertible promissory note in the aggregate principal amount of $132,500, for a purchase price of $132,500, which the Company refers to as the Initial Hanover PIPE Note. On October 19, 2012, in a private placement pursuant to a note purchase agreement, the Company issued Hanover a convertible promissory note in the aggregate principal amount of $132,500, for a purchase price of $132,500, which is referred to as the Second Hanover PIPE Note, which, together with the Initial Hanover PIPE Note is referred to as the Hanover PIPE Notes. The Hanover PIPE Notes bear interest at a rate of 12%, which interest accrues, but does not become payable until maturity or acceleration of the principal of such Hanover PIPE Notes. The Hanover PIPE Notes are convertible into shares of the Company’s Common Stock at a conversion price equal to 65% of the arithmetic average of the five lowest closing trading prices for the Common Stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Hanover PIPE Notes mature eight months from their respective issuance dates. To the extent Hanover does not elect to convert the Hanover PIPE Notes as described above, the principal amount and interest of such Hanover PIPE Notes shall be payable in cash at maturity. The Hanover PIPE Notes may be converted at any time by Hanover, at its option, in whole or in part. The Hanover PIPE Notes include a limitation on conversion, which provides that at no time will Hanover be entitled to convert any portion of the Hanover PIPE Notes, to the extent that after such conversion, Hanover (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

Unrealized losses on the mark-to-market of the notes which amounted to $97,791, for the period from the dates of issuance (September 19 and October 19, 2012) through October 31, 2013 were recorded as non-cash expense. The Hanover PIPE Notes were recorded on the balance sheet, at fair value, of approximately $363,000.

During the twelve months ended October 31, 2013, the note-holder converted principal of $365,000 into 97,333 shares of the Company’s Common Stock at a conversion rate of $3.75 per share. During the twelve months ended October 31 2013, the Company recognized interest expense of approximately $72,000 in order to accrete the unamortized debt discount back to the notes’ principal through the dates of conversion.

As of October 31, 2014, there were no remaining Hanover PIPE Notes.

Magna Note

In October 2012, pursuant to the terms of various Assignment Agreements, which the Company refers to as the Assignment Agreements, Magna Group, LLC, an affiliate of Hanover, which is referred to as Magna, acquired $400,076 in aggregate principal amount of the Company’s outstanding convertible notes from certain third parties and entered into agreements to acquire an additional $340,523 in aggregate principal amount of its outstanding convertible notes from other third parties. Pursuant to the terms of such Assignment Agreements, the Company delivered two convertible notes to Magna in an aggregate principal amount of $740,599, in anticipation of the closing of all of the transactions contemplated by such Assignment Agreements. On October 25, 2012, the convertible note in the aggregate principal amount of $617,723 previously delivered to Magna was exchanged for a new convertible note in the aggregate principal amount of $400,076, convertible into shares of Common Stock, which the Company refers to as the Magna Exchange Note, to reflect such portion of the convertible notes actually issued as of October 25, 2012 pursuant to the Assignment Agreements, and the remaining convertible note in the aggregate principal amount of $122,876 previously delivered to Magna was returned to us and cancelled. The Magna Exchange Note bears interest at a rate of 6%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Magna Exchange Note. The Magna Exchange Note is convertible into shares of the Company’s Common Stock at a conversion price equal to 73% of the arithmetic average of the five lowest closing trading prices for the Common Stock during the 10 trading day period ending on the lowest complete trading day prior to the applicable conversion date. The Magna Exchange Note matures on October 17, 2013. To the extent Magna does not elect to convert the Magna Exchange Note as described above, the principal amount and interest of the Magna Exchange Note shall be payable in cash at maturity. Upon the closing of the remaining transactions contemplated by such applicable Assignment Agreements, the Company is obligated to issue additional convertible notes in the form of the Magna Exchange Note with respect to the outstanding $ 340,523 in aggregate principal amount of convertible notes held by the third party signatories to the other Assignment Agreements.

The Magna Exchange Note may be converted at any time by Magna, at its option, in whole or in part. The Magna Exchange Note includes a limitation on conversion, which provides that at no time will Magna be entitled to convert any portion of the Magna Exchange Note, to the extent that after such conversion, Magna (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

During the twelve months ended October 31, 2013, Magna converted the remaining approximately $300,000 in principal into 80,992 shares of the Company’s Common Stock at prices ranging from $3.21 to $4.14, resulting in non-cash expense for the period of approximately $ 44,000 resulting from the difference between the amount of principal converted and the fair value of the shares issued as a result of the conversion. In addition, Magna converted another approximately $341,000 in principal into 182,344 shares of the Company’s Common Stock at prices ranging from $3.16 to $3.49, resulting in non-cash expense of approximately $281,000 resulting from the difference between the amount of principal converted and the fair value of the shares issued as a result of these conversions.

As of October 31, 2014, the Magna Exchange Note had been converted in full and no longer remained outstanding.

Chris French

On September 27, 2012, in a private placement pursuant to a note purchase agreement, the Company issued its employee Christine French a convertible promissory note in the aggregate principal amount of $25,000, for a purchase price of $25,000, which is referred to as the French Note. The French Note bears interest at a rate of 12%, compounded annually. The French Note is convertible into shares of the Company’s Common Stock at a conversion price equal to the arithmetic average of the five lowest closing trading prices for the Common Stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The French Note matures one month from its issuance date. Additionally, Ms. French will receive a warrant, which the Company refers to as the French Warrant, to purchase such number of shares of its Common Stock equal to 50% of such number of shares of its Common Stock issuable upon conversion of the French Note at an exercise price equal to the conversion price then in effect. These warrants have not yet been issued. The French Warrant may be exercised on a cashless basis under certain circumstances. The French Note and the French Warrant each include a limitation on conversion or exercise, as applicable, which provides that at no time will Ms. French be entitled to convert any portion of the French Note or French Warrant, to the extent that after such conversion or exercise, as applicable, Ms. French (together with her affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

During the twelve months ended October 31, 2013, the Company converted principal of $25,000 of a note issued to Chris French plus accrued interest of approximately $633, into 4,527 shares of its Common Stock at a conversion price of $5.625 per share. In addition, the Company issued a warrant to acquire 2,263 shares, which expires on October 26, 2015 and revalued the warrant liability, at October 31, 2013, with an exercise price of $5.625, resulting in non-cash expense of approximately $21,000 resulting from the difference between the fair value of the note as shown on the balance sheet plus accrued interest to-date and the fair value of the shares issued as a result of the conversion.

As of October 31, 2014, the French Note no longer remained outstanding.

Asher

On September 11, 2012, in a private placement pursuant to a note purchase agreement, the Company issued Asher Enterprises, Inc., which is referred to as Asher, a convertible promissory note in the aggregate principal amount of $103,500, for a purchase price of $100,000, which is referred to as the Asher Note. The Asher Note bears interest at a rate of 8%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Asher Note. The Asher Note is convertible into shares of the Company’s Common Stock at a conversion price equal to 61% of the arithmetic average of the five lowest closing trading prices for the Common Stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Asher Note matures on June 13, 2013, nine months from its issuance date. The Asher Note may be converted by Asher, at its option, in whole or in part. The Asher Note includes a limitation on conversion, which provides that at no time will Asher be entitled to convert any portion of the Asher Note, to the extent that after such conversion, Asher (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

During the year ended October 31, 2013, Asher converted the above principal of $153,500 and accrued interest of $6,140 into approximately 44,161 shares of the Company’s Common Stock at a conversion prices ranging from $3.43 /share to $3.90 /share.

On May 1, 2013, in a private placement pursuant to a note purchase agreement, the Company issued Asher a convertible promissory note in the aggregate principal amount of $203,500, for a purchase price of $200,000, which it refers to as the Third Asher Note. The Third Asher Note bears interest at a rate of 8%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Third Asher Note. The Third Asher Note is convertible into shares of the Company’s Common Stock at a conversion price equal to 65% of the arithmetic average of the five lowest closing trading prices for the Common Stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Third Asher Note matures on February 3, 2014, nine months from its issuance date. The Third Asher Note may be converted by Asher, at its option, in whole or in part and included a limitation on conversion, which provides that at no time would Asher be entitled to convert any portion of the Third Asher Note, to the extent that after such conversion, Asher (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock of the Company as of such date.

The Company recorded interest expense of $77,737 resulting from the prepayment penalty associated with the Third Asher Note. During the twelve months ended October 31, 2013, the Company paid off the Third Asher Note in the amount of $281,237.

As of October 31, 2014, the Third Asher Note no longer remained outstanding.

On July 12, 2013, in a private placement pursuant to a note purchase agreement, the Company issued Asher a convertible promissory note in the aggregate principal amount of $103,500, for a purchase price of $100,000, which it refers to as the Fourth Asher Note. The Fourth Asher Note bears interest at a rate of 8%, which interest accrues, but does not become payable until maturity or accelerations of the principal of the Fourth Asher Note. The Fourth Asher Note is convertible into shares of the Company’s Common Stock at a conversion price equal to 65% of the arithmetic average of the five lowest closing trading prices for the Common Stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Fourth Asher Note matures on April 16, 2014, nine months from its issuance date. The Fourth Asher Note may be converted by Asher, at its option, in whole or in part and included a limitation on conversion, which provides that at no time will Asher be entitled to convert any portion of the Fourth Asher Note, to the extent that after such conversion, Asher (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock of the Company as of such date.

The Company recorded interest expense of $27,917 resulting from the prepayment penalty associated with the Fourth Asher Note. During the twelve months ended October 31, 2013, the Company paid off the Fourth Asher Note in the amount of $131,417.

As of October 31, 2014, the Fourth Asher Note no longer remained outstanding.

Yvonne Paterson

On September 25, 2012, in a private placement pursuant to a note purchase agreement, the Company issued its affiliate Dr. Yvonne Paterson a convertible promissory note in the aggregate principal amount of $100,000, for a purchase price of $100,000, which is referred to as the Paterson Note. The Paterson Note bears interest at a rate of 12%, compounded annually. The Paterson Note is convertible into shares of the Company’s Common Stock at a conversion price equal to the arithmetic average of the five lowest closing trading prices for the Common Stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Paterson Note matures one month from its issuance date. Additionally, Dr. Paterson will receive a warrant, which is referred to as the Paterson Warrant, to purchase such number of shares of the Company’s Common Stock equal to 50% of such number of shares of its Common Stock issuable upon conversion of the Patterson Note at an exercise price equal to the conversion price then in effect. These warrants have not yet been issued. The Paterson Warrant may be exercised on a cashless basis under certain circumstances. The Paterson Note and the Paterson Warrant each include a limitation on conversion or exercise, as applicable, which provides that at no time will Dr. Paterson be entitled to convert any portion of the Paterson Note or Paterson Warrant, to the extent that after such conversion or exercise, as applicable, Dr. Paterson (together with her affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

During the twelve months ended October 31, 2013, the Company converted principal of $100,000 of a note issued to Yvonne Paterson plus accrued interest of approximately $2,532, into 18,107 shares of its Common Stock at a conversion price of $5.625 per share. In addition, the Company issued a warrant to acquire 9,054 shares, which expires on October 26, 2015 and revalued the warrant liability, at October 31, 2013, with an exercise price of $5.625, resulting in non-cash expense of $32,000 resulting from the difference between the fair value of the note as shown on the balance sheet plus accrued interest to-date and the fair value of the shares issued as a result of the conversion.

As of October 31, 2014, the Paterson Note no longer remained outstanding.

James Patton

On August 2, 2012, in a private placement pursuant to a note purchase agreement, the Company issued Dr. James Patton, a member of its board of directors, a convertible promissory note, which is referred to as the Patton Note, in the principal amount of $66,667 for a purchase price of $50,000. The Patton Note was issued with an original issue discount of 25%. Dr. Patton paid $0.75 for each $1.00 of principal amount of the Patton Note purchased. The Patton Note is convertible into shares of the Company’s Common Stock at a per share conversion price equal to $0.15. Additionally, Dr. Patton received a warrant, which is referred to as the Patton Warrant, to purchase such number of shares of the Company’s Common Stock equal to 50% of such number of shares of its Common Stock issuable upon conversion of the Patton Note at an exercise price of $0.15 per share. The Patton Note and Patton Warrant also provide that on December 1, 2012, solely to the extent the conversion price of the Patton Note or the exercise price of the Patton Warrant, as applicable, is less than the Market Price (as defined in the Patton Note or the Patton Warrant, as applicable), such conversion price or exercise price, as applicable, shall be reduced to such Market Price. The Patton Note matures on August 2, 2013. The Company may redeem the Patton Note under certain circumstances. The Patton Warrant is exercisable at any time on or before August 2, 2017. The Patton Warrant may be exercised on a cashless basis under certain circumstances. The Patton Note and the Patton Warrant each include a limitation on conversion or exercise, as applicable, which provides that at no time will Dr. Patton be entitled to convert any portion of the Patton Note or Patton Warrant, to the extent that after such conversion or exercise, as applicable, Dr. Patton (together with his affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

During the twelve months ended October 31, 2013, the Company converted the principal amount of the Patton Note, of $66,667, into 21,092 shares at a conversion price of $3.16. The Company recorded non-cash income of approximately $94,000 for the twelve months ended October 31, 2013, respectively. Accretion of the discount amounted to $3,355, for the twelve months ended October 31, 2013. The Patton Warrants, in the amount of 1,778, remained outstanding at October 31, 2014 and were revalued as part of the warrant liability at October 31, 2014 and 2013.

As of October 31, 2014, the Patton Note no longer remained outstanding.

Redwood Management LLc

On June 21, 2013, the Company entered into a bridge financing arrangement with Redwood Management, LLC (“Redwood”), an accredited investor, for which Aegis Capital Corp. acted as placement agent and received an 8 % fee based on the consideration paid to to the Company. Accordingly, on June 21, 2013, the Company entered into a Securities Purchase Agreement with Redwood Management LLC, which it refers to as Redwood, and in a private placement thereunder issued Redwood a convertible promissory note in the aggregate principal amount of $277,777, for a purchase price of $250,000 (or a 10% original issue discount), which it refers to as the Redwood Note. The Redwood Note bears interest at a rate of 5%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Redwood Note. The Redwood Note is convertible into shares of the Company’s Common Stock at a conversion price equal to the lesser of (i) $6.25, or (ii) 70% of the ten day average value weighted average price (“VWAP”) for the ten trading days immediately preceding the conversion date. The Redwood Note matures on December 30, 2013, six months from its issuance date. The Redwood Note may be converted by Redwood, at its option, in whole or in part. The Redwood Note includes a limitation on conversion, which provides that at no time will Redwood be entitled to convert any portion of the Redwood Note, to the extent that after such conversion, Redwood (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

The Company agreed to reserve at least 2.5 times the number of shares of its Common Stock actually issuable upon full conversion of the Redwood Note, and not to take certain actions without Redwood’s consent and granted Redwood the right, at its election, to participate in future financings subject to certain limited exceptions. So long as the Company is not in default, and provided it has given 20 days prior written notice, it may prepay the Redwood Note in full at any time at a premium of 110% of the amount owed (which multiple increases 4 months after the issuance date). In addition, if the Company completes a financing of $7,000,000 or more, Redwood has the right, at its election, to require the Company to repay the Redwood Note in full on the closing date of such financing on the same payment terms as noted in the preceding sentence. The Redwood Note includes customary event of default provisions, and provide for a default rate of 14%.

During the twelve months ended October 31, 2013, the Company converted the Redwood Note, with a principal amount of $ 277,777 and accrued interest of approximately $ 4,300 into 125,000 shares of its Common Stock, at an conversion price of $ 2.33 per share.

As of October 31, 2014, the Redwood Note no longer remained outstanding.

Issuance of Notes Collateralized by NOLs and R&D Tax Credits

On August 20, 2013, in a private placement pursuant to a note purchase agreement, the Company issued an accredited investor a secured convertible promissory note in the aggregate principal amount of $108,000, for a purchase price of $100,000. On September 18, 2013, the Company borrowed an additional $150,000 from this accredited investor and amended and restated the terms of the August note and issued this investor 12,000 shares of its Common Stock. As amended and restated, this note has an aggregate principal amount of $258,000, bears interest at a rate of 20% per annum and is due February 21, 2014, nine months after its original issuance date. To secure prompt payment under the note, the Company granted the holder a continuing security interest in all net proceeds the Company receives up to the aggregate amount of $258,000 plus accrued interest from the sale of its net operating loss and or research and development tax credits through the New Jersey Economic Development Program. In October 2013, the Company paid approximately $278,000 (principal and accrued interest) in full satisfaction of its obligation under this note.

As of October 31, 2014, this note no longer remained outstanding.

Common Stock Purchase Warrants and Warrant Liability

12 Months Ended

Oct. 31, 2014

Common Stock Purchase Warrants And Warrant Liability

Common Stock Purchase Warrants and Warrant Liability

8. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

Warrants

As of October 31, 2014, there were outstanding warrants to purchase 4,158,092 shares of the Company’s Common Stock with exercise prices ranging from $2.76 to $21.25 per share. Information on the outstanding warrants is as follows:

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Common Stock Purchase Warrant	$	18.75		28,632	May 2015	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		10,059	October 2015	Oct 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		17,706	May 2015 – January 2016	December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		13,333	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	7.77-21.25		112,460	December 2014 – April 2015	Bridge Notes
Common Stock Purchase Warrant	$	18.75		376	N/A	Vendor & Other
Common Stock Purchase Warrant	$	10.625-18.75		7,855	January 2015 – May 2017	Placement Agent – Convertible Debt Financing
Common Stock Purchase Warrant	$	5.00		20,392	October 2018	Former Officer
Common Stock Purchase Warrant	$	4.90		30,154	September 2015	Consultant
Common Stock Purchase Warrant	$	2.76-5.52		277,055	December 2015 – March 2024	Stock Purchase Agreement
Common Stock Purchase Warrant	$	5.625-18.75		13,095	October 2015 – August 2017	August – September 2012 Convertible Promissory Notes
Common Stock Purchase Warrant	$	5.00		3,306,200	October 2018	Advaxis Public Offering
Common Stock Purchase Warrant	$	3.75-5.00		320,775	October 2018 – March 2019	Representative – Advaxis Public Offering
		Grand Total		4,158,092

As of October 31, 2013, there were outstanding warrants to purchase 4,265,262 shares of the Company’s Common Stock with exercise prices ranging from $2.76 to $21.25 per share. Information on the outstanding warrants is as follows:

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Exchange Warrants - Nonexercisable	$	18.75		278,329	October 2014	July 2012 Exchanges
Common Stock Purchase Warrant	$	18.75		28,632	May 2015	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		11,628	October 2014 – October 2015	Oct 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		17,706	May 2015 – January 2016	December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75		13,333	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	9.24-21.25		293,115	December 2013 – April 2015	Bridge Notes
Common Stock Purchase Warrant	$	18.75		376	N/A	Vendor & Other
Common Stock Purchase Warrant	$	10.625-18.75		29,883	May 2014 – May 2017	Placement Agent – Convertible Debt Financing
Common Stock Purchase Warrant	$	5.00		20,392	October 2018	Former Officer
Common Stock Purchase Warrant	$	4.90		30,154	September 2015	Consultant
Common Stock Purchase Warrant	$	2.76-4.375		23,994	December 2015 – August 2016	Stock Purchase Agreement
Common Stock Purchase Warrant	$	5.625-18.75		13,095	October 2015 – August 2017	August – September 2012 Convertible Promissory Notes
Common Stock Purchase Warrant	$	5.00		3,306,250	October 2018	Advaxis Public Offering
Common Stock Purchase Warrant	$	5.00		198,375	October 2018	Representative – Advaxis Public Offering
		Grand Total		4,265,262

A summary of changes in warrants for the year ended October 31, 2014 is as follows:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding and Exercisable Warrants at October 31, 2013		4,265,262		$	6.71		4.22	$	22,208
Issued		412,693		$	4.97
Exercised		(50	)	$	5.00
Expired		(519,813	)	$	15.01
Outstanding and Exercisable Warrants at October 31, 2014		4,158,092		$	5.42		3.94	$	9,518

At October 31, 2014, the Company had approximately 4.0 million of its total 4.2 million outstanding warrants classified as equity (equity warrants). At October 31, 2013, the Company had approximately 3.7 million of its total 4.3 million outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the shareholders equity section of the balance sheet. The Company’s equity warrants can only be settled through the issuance of shares and are not subject to anti-dilution provisions.

At October 31, 2014, the Company had approximately 123,000 of its total 4.2 million outstanding warrants classified as liability warrants (Common Stock warrant liability). The fair value of the warrant liability, as of October 31, 2014 was approximately $32,000. At October 31, 2013, the Company had approximately 0.6 million of its total 4.3 million outstanding warrants classified as liability warrants (Common Stock warrant liability). The fair value of the warrant liability, as of October 31, 2013, was approximately $0.6 million. In fair valuing the warrant liability, at October 31, 2014 and October 31, 2013, the Company used the following inputs in its BSM:

	10/31/2014			10/31/2013

Exercise Price:	$	2.76-21.25		$	2.76-21.25

Stock Price	$	3.18		$	3.74

Expected term:		4 -1006 days			61-1371 days

Volatility %		55.41% -129.38	%		98.89% -186.24	%

Risk Free Rate:		.01%-1.62	%		.035%-.94	%

Warrant Liability/Embedded Derivative Liability

Warrant Liability

As of October 31, 2014, the Company had approximately 123,000 of its total approximately 4.2 million total warrants classified as liabilities (liability warrants). All of these 123,000 liability warrants are outstanding. The Company utilizes the BSM to calculate the fair value of these warrants at issuance and at each subsequent reporting date. For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM, to account for the various possibilities that could occur due to changes in the inputs to the BSM as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the warrants at the reporting date. At October 31, 2014, approximately 60,000 of the 123,000 liability warrants are subject to weighted-average anti-dilution provisions. A certain number of liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the Common Stock purchase warrant). Any changes in the fair value of the warrant liability (i.e. - the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported on the statement of operations.

As of October 31, 2013, the Company had approximately 565,000 of its total approximately 4.3 million total warrants classified as liabilities (liability warrants). Of these 565,000 liability warrants, approximately 287,000 warrants are outstanding and approximately 278,000 warrants are exchange warrants – nonexercisable. The Company utilizes the BSM to calculate the fair value of these warrants at issuance and at each subsequent reporting date. For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM, to account for the various possibilities that could occur due to changes in the inputs to the BSM as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the warrants at the reporting date. At October 31, 2013, approximately 203,000 of the 565,000 liability warrants are subject to anti-dilution provisions. A certain number of liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the Common Stock purchase warrant). Any changes in the fair value of the warrant liability (i.e. - the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported on the statement of operations.

At October 31, 2014 and October 31, 2013, the fair value of the warrant liability was $32,091 and $646,734, respectively. For the twelve months ended October 31, 2014 and 2013, the Company reported income of $619,089 and a loss of $1,504,465, respectively, due to changes in the fair value of the warrant liability.

Exercise of Warrants

During the twelve months ended October 31, 2014, an accredited investor exercised 50 warrants at an exercise price of $5.00, resulting in net proceeds to the Company of $250. During the twelve months ended October 31, 2013, an accredited investor exercised 8,889 warrants at an exercise price of $10.625, resulting in net proceeds to the Company of $94,444. During the twelve months ended October 31, 2013, the Company issued 484,876 shares to Tonaquint as a result of cashless exercises of 189,415 warrants per the terms of the December 2012 promissory note in addition to the settlement agreement entered into in October 2013.

Expiration of Warrants

During the twelve months ended October 31, 2014, the Company had 60,069 warrants with anti-dilution provisions, and 459,744 warrants, with no such anti-dilution provisions, expire unexercised.

During the twelve months ended October 31, 2013, the Company had 500 warrants with no anti-dilution provisions, expire unexercised.

Warrants with anti-dilution provisions

Some of the Company’s warrants (approximately 60,000) contain anti-dilution provisions originally set at an exercise price of $25.00 with a term of five years. As of October 31, 2014, these warrants had an exercise price of approximately $7.71. As of October 31, 2013, these warrants had an exercise price of approximately $9.24. If the Company issues any Common Stock, except for exempt issuances as defined in the warrant agreement for consideration less than the exercise price then the exercise price and the amount of warrant shares available would be adjusted to a new price and amount of shares per the “weighted average” formula included in the warrant agreement. For the twelve months ended October 31, 2014, this anti-dilution provision required the Company to issue approximately 37,200 additional warrant shares and the exercise price to be lowered to $7.71. Any future financial offering or instrument issuance below the current exercise price of $7.71 will cause further anti-dilution and re-pricing provisions in approximately 60,000 of the Company’s total outstanding warrants.

For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM, to account for the various possibilities that could occur due to changes in the inputs to the BSM as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company utilized different exercise prices of $7.71 and $6.50, weighting the possibility of warrants being exercised at $7.71 between 40% and 50% and warrants being exercised at $6.50 between 60% and 50%.

As of October 31, 2014, there were outstanding warrants to purchase 4,158,092 shares of the Company’s Common Stock with exercise prices ranging from $2.76 to $21.25 per share.

Embedded Derivative Liability

The Company has convertible features (known as “Embedded Derivatives”) in its outstanding convertible promissory notes. The Embedded Derivatives are recorded as liabilities at issuance. These Embedded Derivatives are valued using the BSM and are subject to revaluation at each reporting date. Any change in fair value between reporting periods will be reported on the statement of operations.

At October 31, 2014 and October 31, 2013, the fair value of the Embedded Derivative Liability was $0 as the related notes were paid off, converted or reached maturity.

The fair value of the Warrants and Embedded Derivatives are estimated using an adjusted BSM model. The Company computes multiple valuations, each quarter, using the BSM model for each derivative instrument to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the derivative at the reporting date. As of October 31, 2014, the fair value of the Warrants and Embedded Derivatives was determined to be approximately $32,000 and $0, respectively. As of October 31, 2013, the fair value of the Warrants and Embedded Derivatives was determined to be approximately $647,000 and $0, respectively. Change in the fair value of the Common Stock warrant liability for the year ended October 31, 2014 was a gain of $619,089 and a loss of $1,504,465 for October 31, 2013.

Commitments and Contingencies

12 Months Ended

Oct. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10. COMMITMENTS AND CONTINGENCIES:

Employment Agreements

In December, 2013, each of the Company’s then executive officers requested to purchase stock directly from the Company at market price. To facilitate such requests, the Company amended each of the then executive officer’s employment agreements so that such officers could make periodic purchases of the Company’s Common Stock at fair market value. Listed below are the annual amounts to be purchased by each executive. On June 5, 2014, the Company and each of Daniel J. O’Connor, Chief Executive Officer and President, Gregory T. Mayes, Executive Vice President, Chief Operating Officer and Secretary, Robert G. Petit, Executive Vice President and Chief Scientific Officer, Sara M. Bonstein, Senior Vice President, Chief Financial Officer and Chris L. French, Vice President, Regulatory & Medical Affairs (each an “Executive”), voluntarily entered into a further amendment (each, an “Amendment” and collectively, the “Amendments”) to their respective Employment Agreements (each, an “Employment Agreement”). The Amendments now provide that the respective stock purchases will occur on the last business day of each calendar month and will be effected through a direct purchase from the Company at a purchase price equal to the closing price of the Common Stock on the purchase date. The Company has not filed a Registration Statement on Form S-8 (or any other registration form) to cover the shares of Common Stock issuable pursuant to the Amendments.

The allocation between the cash and equity components of each Executive’s base salary is as follows:

	ANNUALIZED		For the Year Ended October 31, 2014
	Annual Amount to be Purchased		Gross Purchase				Net Purchase
Executive Officer	$		$		# of shares		$		# of shares
Daniel J. O’Connor	$	81,250	$	68,750		21,687	$	50,891		15,950
David J. Mauro	$	15,750	$	606		190	$	527		165
Gregory T. Mayes	$	19,875	$	16,818		5,305	$	13,801		4,333
Robert G. Petit	$	24,225	$	20,498		6,466	$	16,363		5,159
Sara M. Bonstein	$	16,875	$	10,384		3,355	$	8,038		2,585
Chris L. French	$	10,750	$	8,837		2,785	$	7,475		2,352

For the twelve months ended October 31, 2014, the Company recorded stock compensation expense of $128,241 on the statement of operations representing 40,320 shares of its Common Stock (31,026 shares on a net basis after employee payroll taxes).

As to preserve the Company’s cash resources, in his current Amendment, Mr. O’Connor voluntarily requested to waive and hence forego the scheduled increases in his base salary that were required under his Employment Agreement. Therefore, Mr. O’Connor did not receive an base salary increase or a salary increase for closing a licensing or other strategic transaction.

In addition to the purchases of Common Stock set forth in the above table, Mr. O’Connor has also purchased an additional 72,676 shares of Common Stock out of his personal funds for an aggregate consideration of approximately $313,419. These purchases consisted of the conversion of amounts due under a promissory note of approximately $66,500 for 21,091 shares, 2013 base salary which he elected to receive in Common Stock of approximately $182,919 for 34,752 shares, and purchases of the Company’s Common Stock in the October 2013 and March 2014 public offerings of 13,500 shares for $54,000 and 3,333 shares for $10,000.

Stock Awards

In December 2013, the Company granted stock awards and restricted stock units (“RSUs”) to employees, executive officers and directors under the 2011 Omnibus Incentive Plan.

	●	Management Team Bonuses: Executive officers received a portion of their year-end performance bonus (with a total fair value of approximately $129,000) in the aggregate amount of 31,846 shares of the Company’s Common Stock (21,389 on a net basis after employee payroll taxes).

	●	Equity grant to executive officers: The Company granted 525,000 shares of its Common Stock to its executive officers. Of these shares, 105,000 shares of its our Common Stock (63,949 shares on a net basis after employee payroll taxes) vested immediately, with a total fair value of $423,150, and were issued and recorded as a charge to income during the twelve months ended October 31, 2014. The remaining 420,000 shares represent RSUs and are to vest in equal installments over twelve quarters such that 100% of the RSUs have vested by the third anniversary of the grant date. These RSU’s are subject to availability of shares under the 2011 Omnibus Incentive Plan and are subject to forfeiture under certain conditions. During the twelve months ended October 31, 2014, $879,883 was charged to stock compensation expense, representing 218,333 shares of the Company’s Common Stock (133,903 shares on a net basis after employee payroll taxes), and 80,000 shares were forfeited. During the twelve months ended October 31, 2014, the 2011 Omnibus Incentive Plan was increased from 520,000 to 2,120,000.

	●	Equity grant to non-executive employees: The Company granted approximately $101,250 of the aggregate base salary compensation, or 25,124 shares of Common Stock, to be issued to its non-executive employees. Of this grant, $20,250 vested immediately and 5,025 shares of Common Stock (3,685 shares on a net basis after employee payroll taxes) were issued to non-executive employees. The remaining $81,250, or 20,099 shares of Common Stock, represents RSUs and are to vest in equal installments over twelve quarters such that 100% of the RSUs have vested by the third anniversary of the grant date. In addition an employee received 100 shares of the Company’s Common Stock (91 shares on a net basis after employee payroll taxes) with a total fair value of $336 award for employee excellence. During the twelve months ended October 31, 2014, $45,719 was charged to stock compensation expense, representing 11,362 shares of the Company’s Common Stock (8,758 shares on a net basis after employee payroll taxes) and 2,316 shares of Common Stock were forfeited.

	●	All of these non-executive equity grants are currently available under the 2011 Omnibus Incentive Plan. As of October 31, 2014, all vested shares have been issued.

The Company recognizes the fair value of those vested shares in the statement of operations in the period earned.

Director Compensation

During December 2013, the Board of Directors deemed it advisable and in the best interests of the Company to issue shares of RSUs as compensation for all 2013 Board of Director committee meetings and to cancel any options designated for issuance related to those 2013 committee and board meetings and to further issue shares of RSUs for all fiscal years 2013 through 2016 Board of Director committee meetings in the aggregate amount of 50,000 shares of RSUs to each non-employee director (excluding Mr. Moore). The RSU grant will vest quarterly over three years such that 100% of the RSU will be vested on the third anniversary date (December 2016). During the twelve months ended October 31, 2014, $340,039 was charged to stock compensation expense, representing 84,377 shares of the Company’s Common Stock.

During December 2013, the Board of Directors deemed it advisable and in the best interests of the Company to amend a certain provision of the consulting agreement with Mr. Moore, which took effect August 19, 2013 and issue 37,500 restricted stock units (RSU’s). The RSU grant will vest quarterly over three years such that 100% of the RSU will be vested on the third anniversary date (December 2016). Since Mr. Moore was not nominated for re-election, only 10,976 RSUs vested through his current term on the Board. Accordingly, $46,099 was charged to stock compensation expense for the year ended October 31, 2014.

Legal Proceedings

Iliad Research and Trading

On March 24, 2014, Iliad Research and Trading, L.P. (“Iliad”) filed a complaint (the “Complaint”) against the Company in the Third Judicial District Court of Salt Lake County, Utah, purporting to assert claims for breach of express and implied contract. Specifically, Iliad alleged that the Company granted a participation right to Tonaquint, Inc. (“Tonaquint”) in a securities purchase agreement between Tonaquint and the Company, dated as of December 13, 2012 (the “Purchase Agreement”), pursuant to which Tonaquint was entitled to participate in any transaction that the Company structured in accordance with Section 3(a)(9) or Section 3(a)(10) of the Securities Act of 1933, as amended. Iliad further alleged that the settlement that the Company entered into with Ironridge Global IV, Ltd. (“Ironridge”), pursuant to which the Company issued certain shares of its Common Stock to Ironridge in reliance on the Section 3(a)(10) exemption, occurred without adequate notice for Tonaquint to exercise its participation right. In addition, Iliad alleged that it acquired all of Tonaquint’s rights under the Purchase Agreement in April 2013. On May 9, 2014, the Company filed papers in support of its motion to dismiss the Complaint in its entirety. On June 2, 2014, Iliad filed an amended complaint (the “Amended Complaint”), which purported to add claims against the Company under the federal and Utah securities laws and for common law fraud. On June 30, 2014, the Company removed the action to the United States District Court for the District of Utah. On August 1, 2014, after the Court issued its Order Granting Stipulated Motion for Leave to File Second Amended Complaint, Iliad filed a Second Amended Complaint (the “SAC”), which purports to add a sixth claim for conversion. Iliad seeks “damages in an amount to be determined at trial” (though the common law fraud damages alone are alleged to be “greater than $300,000”) plus interest, attorneys’ fees and costs. Iliad has also asked for punitive damages in connection with its claims under the Utah Securities Act (equal to three times its actual damages), common law fraud and conversion. The Company intends to continue to defend itself vigorously.

Brio Capital L.P.

On March 22, 2013, the Company was notified that Brio Capital L.P. which the Company refers to as Brio, had filed a lawsuit against Advaxis, in the Supreme Court of the State of New York, County of New York, titled Brio Capital L.P. v. Advaxis Inc., Case No. 651029/2013, which the Company refers to as the Action. The complaint in the Action alleges, among other things, that Advaxis breached the terms of certain warrants to purchase shares of its Common Stock that was originally issued to Brio on October 17, 2007 and on June 18, 2009, and that Brio has suffered damages as a result thereof. Brio’s complaint seeks (i) a preliminary and permanent injunction directing the Company to issue to Brio 21,742 shares of the Company’s Common Stock, along with the necessary corporate resolutions and legal opinions to enable Brio to sell such Common Stock publicly without restriction; and (ii) damages of at least $500,000 (in an amount to be determined at trial), along with interest, costs and attorneys’ fees related to the Action. On April 15, 2013, in partial resolution of the Brio lawsuit, the Company issued 21,742 shares of Common Stock and provided certain corporate resolutions and legal opinions necessary to enable Brio to sell such Common Stock publicly without restriction. On October 29, 2013, the Company entered into a settlement agreement with Brio to settle the remaining claims under the Action, which agreement was to become binding only when approved by the court at a fairness hearing. The parties later agreed to amend the settlement by the Company paying Brio $205,000 in full settlement of all claims related to this lawsuit in exchange for a release of claims and cancellation of the warrants. The matter is now finally settled and the Action dismissed with prejudice on October 29, 2013.

Maxim Group, LLC

On August 19, 2013, the Company entered into an agreement with Maxim Group LLC, or Maxim to terminate a July 2012 engagement agreement between the parties, pursuant to which Maxim asserted claims for unpaid fees related to the introduction of investors to the Company and services provided. As consideration for terminating the agreement, the Company agreed to pay Maxim approximately $589,000 in monthly installment payments in either cash or shares of its Common Stock, and a warrant to purchase 30,154 shares of its Common Stock at an exercise price of $4.90 per share. Additionally, in order to move the settlement forward, the Company reluctantly agreed to pay Maxim an additional $150,000 upon the completion of a contemplated public offering of securities. On September 17, 2013, the Company issued 25,582 shares of its Common Stock as an installment payment under this agreement and also issued the warrant to acquire 30,154 shares of its Common Stock at $4.90 per share, and on September 27, 2013, the Company issued 158,385 shares of its Common Stock to satisfy the remaining amount owed under this agreement. Maxim rejected the delivery of these 158,385 shares and claimed that the Company may not prepay its obligations under the agreement notwithstanding any language to the contrary in the agreement. Upon receipt of the rejected shares, Advaxis cancelled the issuance of such shares. Upon the completion of its public offering in October, 2013 the Company paid the aforementioned $150,000 and commenced final settlement of the disputed amounts owed. On or about November 14, 2013 Maxim initiated a proceeding by confession of judgment in New York State Court to recover monies it believed Advaxis owed it under the Termination Agreement in the amount of $484,710. On November 15, 2013 the New York County Clerk’s office entered a judgment in favor of Maxim. On or about November 22, 2013 Maxim mailed a Notice of Entry to Advaxis and the parties decided to settle the dispute without any admission of liability or wrongdoing and on December 23, 2013 the parties executed a Settlement Agreement and Releases. On December 27, 2013 the Company paid Maxim $285,000 in final settlement of all matters related to their claim.

The Company is from time to time involved in legal proceedings in the ordinary course of its business. The Company does not believe that any of these claims and proceedings against us is likely to have, individually or in the aggregate, a material adverse effect on its financial condition or results of operations.

Consulting Agreement; Debt Conversion/Repayment

On August 19, 2013, the Company entered into a consulting agreement with Mr. Thomas A. Moore, a former director of the Company and its former Chief Executive Officer, pursuant to which Mr. Moore will continue to assist the Company in exchange for (i) receiving an aggregate of approximately $350,000, paid in installments over the course of the one year consulting period, (ii) reimbursement by the Company for any costs associated with or incurred by Mr. Moore for participation in a group health plan and (iii) a grant of 37,500 RSUs that will vest quarterly over three years. Since Mr. Moore was not nominated for re-election, only 10,976 RSUs vested through his current term on the Board. The one-year consulting agreement automatically terminated on August 18, 2014.

Following Mr. Moore’s termination of his engagement as a consultant as provided in the agreement, Mr. Moore was entitled to payment of any earned or accrued but unpaid compensation and, provided that Mr. Moore executes a separation agreement and general release, a one-time lump sum $350,000 disengagement payment, subject to all applicable withholdings and deductions. As of October 27, 2014, the disengagement payment was paid in full.

Numoda

On June 19, 2009, the Company entered into a master agreement and on July 8, 2009, the Company entered into a Project Agreement with Numoda Corporation (“Numoda”), to oversee Phase 2 clinical activity with ADXS-HPV for the treatment of invasive cervical cancer and CIN.

Numoda and the Company are in a dispute regarding the amounts outstanding under these agreements. Numoda had taken the position that it was owed approximately $540,000 while the Company believed that the amount due to Numoda should be substantially less than that amount. The Company intends to continue to defend itself vigorously.

Merck & Co., Inc.

On August 22, 2014, we entered into a Clinical Trial Collaboration and Supply Agreement (the “Merck Agreement”) with Merck, pursuant to which the parties will collaborate on a Phase 1/2 dose-escalation and safety study. The Phase 1 portion of the study will evaluate the safety of our Lm-LLO based immunotherapy for prostate cancer, ADXS31-142 (the “Advaxis Compound”) as monotherapy and in combination with KEYTRUDA® (pembrolizumab), Merck’s humanized monoclonal antibody against PD-1, (the “Merck Compound”) to determine a recommended Phase 2 combination dose. The Phase 2 portion will evaluate the safety and efficacy of the Advaxis Compound in combination with the Merck Compound. Both phases of the study will be in patients with previously treated metastatic castration-resistant prostate cancer. A joint development committee, comprised of equal representatives from both parties, is responsible for coordinating all regulatory and other activities under, and pursuant to, the Merck Agreement.

Each party is responsible for their own internal costs and expenses to support the study, while we will be responsible for all third party costs of conducting the study. Merck will be responsible for manufacturing and supplying the Merck Compound. We will be responsible for manufacturing and supplying the Advaxis Compound. We will be the sponsor of the study and hold the IND related to the study.

All data and results generated under the study (“Collaboration Data”) will be jointly owned by the parties, except that ownership of data and information generated from sample analysis to be performed by each party on its respective compound will be owned by the party conducting such testing. All rights to all inventions and discoveries, which claim or cover the combined use of the Advaxis Compound and the Merck Compound shall belong jointly to the parties. Inventions and discoveries relating solely to the Advaxis Compound, or a live attenuated bacterial vaccine, shall be the exclusive property of us. Inventions and discoveries relating solely to the Merck Compound, or a PD-1 antagonist, shall be the exclusive property of Merck.

The Merck Agreement shall continue in full force and effect until completion of all of the obligations of the parties or a permitted termination.

MedImmune/AstraZeneca

On July 21, 2014, we entered into a Clinical Trial Collaboration Agreement (the “MedImmune Agreement”) with MedImmune, the global biologics research and development arm of AstraZeneca, pursuant to which the parties intend to initiate a Phase 1/2 clinical study in the United States to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with our investigational Lm-LLO cancer immunotherapy, ADXS-HPV, as a combination treatment for patients with advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer. A joint steering committee, composed of equal representatives from both parties, is responsible for various matters associated with the collaboration, including protocol approval, as well as reviewing and monitoring the progress of the study.

MedImmune will be responsible for providing MEDI4736 at no cost, as well as costs related to the proprietary assays performed by MedImmune or a third party on behalf of MedImmune. We will be the sponsor of the study and be responsible for the submission of all regulatory filings to support the study, the negotiation and execution of the clinical trial agreements associated with each study site, and the packaging and labelling of the Advaxis and MedImmune product candidates to be used in the study and the costs associated therewith. For a period beginning upon the completion of the study and the receipt by MedImmune of the last final report for the study and ending one hundred twenty (120) days thereafter (unless extended), MedImmune will be granted first right to negotiate in good faith in an attempt to enter into an agreement with us with respect to the development, regulatory approval and commercialization of ADXS-HPV and MEDI4736 to be used in combination with each other for the treatment or prevention of cancer. Neither party is obligated to enter into such an agreement. In the event the parties do not enter an agreement and we obtain regulatory approval for ADXS-HPV in combination with any PD-1 antibody or PD-L1 antibody, we shall pay MedImmune a royalty obligation and one-time payment.

All intellectual property rights made, conceived or generated through the clinical trials that relate solely to a MedImmune development product shall be owned solely by MedImmune. All intellectual property rights made, conceived or generated through the clinical trials that relate solely to an Advaxis development product shall be owned solely by us. All intellectual property rights made, conceived or generated through the clinical trials that relate to the combination of one or more MedImmune development product and one or more Advaxis development product shall be jointly owned by both parties; provided, however that in the event the parties do not enter into a clinical development and commercialization agreement, we will not exploit, commercialize or license the joint inventions, except for the performance of its obligations under the MedImmune Agreement. MedImmune has the sole right to prosecute and enforce all patents and other intellectual property rights covering all joint inventions and all associated costs will be shared by the parties.

The MedImmune Agreement shall remain in effect until the earlier of (i) permitted termination, (ii) the parties entering into a clinical development and commercialization agreement or expiration of the negotiation period (unless extended), except with respect to rights that survive termination. Either party may terminate the MedImmune Agreement upon thirty (30) days written notice upon material breach of the other party, unless the breach is cured in such period or reasonable actions to cure the breach are initiated and pursued (if the breach is not capable of being cured during the 30-day notice period). In addition, either party may terminate the MedImmune Agreement immediately if the party determines in good faith that the trials may unreasonably affect the safety of trial subjects.

Office & Laboratory Lease

In April 2011, the Company entered into a sublease agreement and relocated its current offices and laboratory to an approximately 10,000 square foot leased facility in Princeton, NJ which approximates $21,000 per month plus utilities. Utility costs are estimated to be approximately $7,200 per month and are capped at approximately $10,700 per month. The Company made an initial payment of approximately $54,000 prior to entering the new facility. Approximately $8,000 of the initial $54,000 payment was for the security deposit and was recorded on the balance sheet as a long-term asset. The sublease agreement has a termination date of November 29, 2015. The Company expects its annual lease costs to approximate $338,000 per year (approximately $1.02 million in the aggregate) until the termination of this agreement in November 2015.

Rent expense for the years ended October 31, 2014 and 2013 was $330,000 and $229,416, respectively.

Sale of Net Operating Losses (NOLs)

The Company may be eligible, from time to time, to receive cash from the sale of its Net Operating Losses under the State of New Jersey NOL Transfer Program. In January 2014, the Company received a net cash amount of $625,563 from the sale of its state NOLs and research and development tax credits for the periods ended October 31, 2010 and 2011. In December 2014, the Company received a net cash amount of $1,731,317 from the sale of its state NOLs and research and development tax credits for the periods ended October 31, 2012 and 2013.

Sharesholders' Equity

12 Months Ended

Oct. 31, 2014

Equity [Abstract]

Sharesholders' Equity

12. SHAREHOLDERS’ EQUITY:

Amendments

At the Annual Meeting of Stockholders of the Company held on July 9, 2014, the stockholders ratified and approved an amendment to the Company’s 2011 Omnibus Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by from 520,000 shares to 2,120,000 shares. Furthermore, the stockholders approved an amendment to the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock from 25,000,000 shares of common stock to 45,000,000 shares of common stock.

Equity Enhancement Program

On October 26, 2012, the Company entered into a Common Stock Purchase Agreement, which it refers to as the Hanover Purchase Agreement, with Hanover, which requires Hanover to purchase up to $10.0 million of shares of its Common Stock over the 24-month term following the effectiveness of the resale registration statement. The purchase price for such shares of Common Stock will be the higher of (i) the minimum price, which the Company refers to as the Floor Price, set forth in its notice electing to effect such issuance, and (ii) 90% of the arithmetic average of the five lowest closing sale prices of the Common Stock during the applicable ten trading day pricing period (or, if less, the arithmetic average of all trading days with closing sale prices in excess of the Floor Price), subject to adjustment. Each trading day with a closing sale price less than the Floor Price is excluded from the calculation of the purchase price and automatically reduces the number of trading days in the applicable pricing period.

In consideration for Hanover’s execution and delivery of the Hanover Purchase Agreement, in connection with the execution and delivery of the Hanover Purchase Agreement, the Company issued Hanover 28,000 Commitment Fee Shares in November 2012. The Company recognized non-cash expense of approximately $157,000 related to the issuance of the Commitment Fee Shares in the twelve months ended October 31, 2013. The Company has also agreed to issue Hanover additional Maintenance Fee Shares of its Common Stock in the event that no shares of Common Stock have been purchased or sold pursuant to the Hanover Purchase Agreement during any calendar quarter during the 24 month term per the terms of the Hanover Purchase Agreement.

The Hanover Purchase Agreement provides for indemnification of Hanover and its affiliates in the event that the Company breaches any of its representations and warranties under the Hanover Purchase Agreement.

In connection with the Hanover Purchase Agreement, on October 26, 2012, the Company entered into a registration rights agreement, which it refers to as the Hanover Registration Rights Agreement, with Hanover, and granted to Hanover certain registration rights related to the Commitment Fee Shares, the Maintenance Fee Shares, and the shares issuable under the Hanover Purchase Agreement. Under the Hanover Registration Rights Agreement, the Company filed with the SEC a registration statement for the purpose of registering the resale of the Common Stock issued to Hanover.

During the twelve months ended October 31, 2013, the Company sold 359,224 shares of its Common Stock under the Equity Enhancement Program for proceeds totaling $2,964,140.

On September 27, 2013, the Company notified Hanover Holdings LLC that it irrevocably commits to suspend any draw-downs under the Common Stock Purchase Agreement without the prior written consent of Aegis Capital Corp. for a six month period from the closing. During the twelve months ended October 31, 2014, the Company and Hanover agreed to terminate the Common Stock Purchase Agreement in exchange for the issuance of 7,080 shares of the Company’s Common Stock valued at $34,126.

Reverse Stock Split

At the annual meeting of shareholders held on June 14, 2013, the Company’s shareholders approved the filing of a Certificate of Amendment to effect a reverse stock split of its issued and outstanding Common Stock, and the filing of a Certificate of Amendment to decrease the total number of its authorized shares of Common Stock. On July 11, 2013, the Company’s Board of Directors authorized a reverse stock split at a ratio of 1-for-125 and approved the implementation of the authorized share capital decrease after the effectiveness of the reverse stock split. Accordingly, the Company amended its Amended and Restated Certificate of Incorporation by the filing of two Certificates of Amendment with the Delaware Secretary of State as follows:(a) on July 11, 2013, to effect a 1-for-125 reverse stock split of its outstanding Common Stock, par value $0.001 per share, to take effect on July 12, 2013 at 4:30 p.m. EDT, and (b) on July 12, 2013, to decrease the total number of authorized shares of Common Stock on a post-reverse stock split basis, so that the total number of shares that the Company has the authority to issue is 30,000,000 shares, of which 25,000,000 shares are Common Stock and 5,000,000 shares are ’‘blank check’’ preferred stock. The reverse stock split was effective at approximately 4:30 p.m. EDT on July 12, 2013, and the share capital decrease took effect thereafter upon filing with the Delaware Secretary of State. All references in this report to number of shares, price per share and weighted average number of shares of Common Stock outstanding prior to this reverse stock split have been adjusted to reflect the reverse stock split on a retroactive basis, unless otherwise noted.

Licensing Agreement – Global BioPharma Inc.

On December 9, 2013, the Company entered into an exclusive licensing agreement for the development and commercialization of ADXS-HPV with Global BioPharma, Inc. (“GBP”), a Taiwanese based biotech company funded by a group of investors led by Taiwan Biotech Co., Ltd (TBC).

GBP plans to conduct registration trials with ADXS-HPV for the treatment of advanced cervical cancer and will explore the use of Advaxis’s lead product candidate in several other indications including lung, head and neck, and anal cancer.

GBP will pay Advaxis event-based financial milestones, an annual development fee, and annual net sales royalty payments in the high single to double digits. In addition, as an upfront payment, GBP made an investment in Advaxis of $400,000 by purchasing from the Company 108,724 shares of its Common Stock at a price of $3.68 per share, GBP also received 100,000 warrants at an exercise price of $5.52 which expire in December 2018.

GBP will be responsible for all clinical development and commercialization costs in the GBP territory. GBP will also reimburse the Company $2.25 million toward its U.S. registrational study, where such payment will help to offset development costs. GBP is committed to establishing manufacturing capabilities for its own territory and to serving as a secondary manufacturing source for Advaxis in the future. Under the terms of the agreement, Advaxis will exclusively license the rights of ADXS-HPV to GBP for Asia, Africa, and former USSR territory, exclusive of India and certain other countries, for all HPV-associated indications. Advaxis retains exclusive rights to ADXS-HPV for the rest of the world.

Licensing Agreement – Aratana Therapeutics

On March 19, 2014, the Company and Aratana entered into a definitive Exclusive License Agreement (the “Aratana Agreement”). Pursuant to the Agreement, Advaxis granted Aratana an exclusive, worldwide, royalty-bearing, license, with the right to sublicense, certain Advaxis proprietary technology that enables Aratana to develop and commercialize animal health products that will be targeted for treatment of osteosarcoma and other cancer indications in animals. Under the terms of the Aratana Agreement, Aratana paid an upfront payment to the Company, of $1 million. As this license has stand-alone value to Aratana (who has the ability to sublicense) and was delivered to Aratana, upon execution of the Aratana Agreement, the Company recorded the $1 million payment as licensing revenue in the three months ended April 30, 2014. Aratana will also pay the Company up to an additional $36.5 million based on the achievement of certain milestones with respect to the advancement of products pursuant to the terms of the Aratana Agreement. In addition, Aratana may pay the Company an additional $15 million in cumulative sales milestones pursuant to the terms of the Aratana Agreement.

Advaxis (i) issued and sold 306,122 shares of Advaxis’s Common Stock to Aratana at a price of $4.90 per share, which was equal to the closing price of the Common Stock on the NASDAQ Capital Market on March 19, 2014, and (ii) issued a ten-year warrant to Aratana giving Aratana the right to purchase up to 153,061 additional shares of Advaxis’s Common Stock at an exercise price of $4.90 per share. In connection with the sale of the Common Stock and warrants, Advaxis received aggregate net proceeds of $1,500,000.

Based on the above licensing agreement, the Company expects to derive the majority of revenue from patent licensing if clinical development is successful. In general, these revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. The intellectual property rights granted may be perpetual in nature, or upon the final milestones being met, or can be granted for a defined, relatively short period of time, with the licensee possessing the right to renew the agreement at the end of each contractual term for an additional minimum upfront payment. The Company recognizes licensing fees when there is persuasive evidence of a licensing arrangement, fees are fixed or determinable, delivery has occurred and collectability is reasonably assured.

JLS Ventures

During the twelve months ended October 31, 2014 the Company issued 200,000 shares of its Common Stock valued at $756,000 to JLS Ventures pursuant to the underlying agreement for investor relations services. As of October 31, 2014, there were no outstanding obligations under this agreement.

Stock Purchase Agreements

During the twelve months ended October 31, 2013, the Company sold 62,981 shares of its Common Stock, to accredited investors, for proceeds totaling approximately $177,250. The Company recorded a liability on its balance sheet for approximately $100,000 (included in proceeds of $177,250) for 45,323 shares (included in the above 62,981 shares), that were not yet delivered to Yenson Co. Ltd as of October 31, 2013 pursuant to a Securities Purchase dated August 28, 2013.

On May 15, 2014, the Company issued 45,323 shares of its Common Stock pursuant to the Securities Purchase Agreement with Yenson.

Series B Preferred Stock Financing

On July 19, 2010, the Company entered into a Series B Preferred Stock Purchase Agreement with Optimus (the “Series B Purchase Agreement”), pursuant to which Optimus agreed to purchase, upon the terms and subject to the conditions set forth therein and described below, up to $7.5 million of the Company’s newly authorized, non-convertible, redeemable Series B preferred stock (“Series B Preferred Stock”) at a price of $10,000 per share. Under the terms of the Series B Purchase Agreement, subject to the Company’s ability to maintain an effective registration statement for the Warrant Shares (as defined below), the Company may from time to time until July 19, 2013, present Optimus with a notice to purchase a specified amount of Series B Preferred Stock. Subject to satisfaction of certain closing conditions, Optimus is obligated to purchase such shares of Series B Preferred Stock on the 10th trading day after the date of the notice.

Holders of Series B preferred stock will be entitled to receive dividends, which will accrue in shares of Series B preferred stock on an annual basis at a rate equal to 10% per annum from the issuance date. Accrued dividends will be payable upon redemption of the Series B preferred stock or upon the liquidation, dissolution or winding up of the Company. In the event the Company redeems all or a portion of any shares of the Series B Preferred Stock then held by Optimus, Optimus shall apply, and the Company may offset, the proceeds of any such redemption to pay down the accrued interest and outstanding principal of the Promissory Note from Optimus.

On September 26, 2013, the Company entered into a Notice of Redemption and Settlement Agreement with Optimus Capital Partners, LLC, a Delaware limited liability company, dba Optimus Life Sciences Capital Partners, LLC, Optimus CG II, Ltd., a Cayman Islands exempted Company and Socius CG II, Ltd., a Bermuda exempted Company, pursuant to which it agreed to redeem the Company’s outstanding shares of Series B Preferred Stock. Pursuant to the agreement, the Company agreed to cancel an outstanding receivable in the amount of $10,633,584 as of the date of the agreement as payment in full of the redemption payment due under the terms of the Series B Preferred Stock and agreed to issue 33,750 shares of its Common Stock having a fair value of $221,400 to settle a disagreement regarding the calculation of the settlement amount under a July 2012 Order and Stipulation. In connection with the redemption, the Company agreed to cancel the outstanding warrant held by Optimus. The Company recorded a charge to Retained Earnings for the accrued dividends payable to date, of $2,877,570 were canceled as part of the redemption transaction. The difference between the accrued dividends payable to-date and the outstanding receivable was written off to Additional Paid-In Capital. The loss on the aforementioned transaction was not material. Accordingly, following such redemption, there are no longer any shares of the Company’s Series B Preferred Stock issued and outstanding.

As of October 31, 2013, the Series B preferred stock had a liquidation preference of $0 due to its redemption as described above. During the twelve months ended October 31, 2014 and 2013, the Company accrued dividends of $0 and $555,000 respectively. The Company also recorded $0 and $149,562 in accrued interest on the promissory notes through the twelve months ended October 31, 2014 and 2013, respectively. The promissory bears interest at 2% per annum which is credited directly to capital.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Oct. 31, 2014

Accounting Policies [Abstract]

Estimates

Estimates

Reclassification

Reclassification

Revenue Recognition

Revenue Recognition

Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. To date, this is yet to occur.

Cash and Cash Equivalents

Cash and Cash Equivalents

Concentration of Credit Risk

Concentration of Credit Risk

Deferred Expenses

Deferred Expenses

Property and Equipment

Property and Equipment

Intangible Assets

Intangible Assets

Deferred Financing Costs

Deferred Financing Costs

Net Loss per Share

Net Loss per Share

	As of October 31,
	2014		2013
Warrants		4,158,092		4,265,262
Stock Options		467,968		467,923
Convertible Debt (using the if-converted method)		3,354		3,354
Total		4,629,414		4,736,539

Research and Development Expenses

Research and Development Expenses

Advertising Expense

Advertising Expense

Advertising costs are charged to operations as incurred. For the years ended October 31, 2014 and 2013 the Company did not incur any advertising costs.

Stock Based Compensation

Stock Based Compensation

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Derivative Financial Instruments

Derivative Financial Instruments

Hybrid Financial Instruments

Hybrid Financial Instruments

Debt Discount and Amortization of Debt Discount

Debt Discount and Amortization of Debt Discount

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Income Taxes

Income Taxes

Nature of Operations and Basis of Presentation (Details Narrative)			12 Months Ended
	Mar. 31, 2014 USD ($) $ / shares shares	Mar. 31, 2014 $ / shares shares	Oct. 31, 2014 USD ($) Patient shares	Oct. 31, 2013 USD ($) shares	Oct. 31, 2012 USD ($)
Number of patients \| Patient			110
Upfront payment			$ 1,000,000
Revenue from license			1,000,000
Net proceeds of issuance of Common Stock			$ 14,580,808	$ 27,438,931
Common stock issued during period \| shares			2,110	6,334
Cash on hand			$ 17,606,860	$ 20,552,062	$ 232
New Jersey Technology BusinessTax [Member]
Proceeds from sale of tax credit			1,700,000
New Jersey Technology BusinessTax [Member] \| December 22, 2014 [Member]
Proceeds from registered direct offering			16,700,000
Underwriters [Member]
Common stock issued during period \| shares		612,000
Exercise price per share \| $ / shares	$ 3.00	$ 3.00
Public Offering [Member]
Common stock issued during period \| shares	4,692,000
Proceeds from issuance or sale of equity, total	$ 14,000,000
Proceeds from underwriting discounts offering expense net	$ 12,700,000
Aratana Therapeutics and Global Biopharma Inc., [Member]
Proceeds from issuance public offering			12,700,000
Net proceeds of issuance of Common Stock			$ 2,000,000

Convertible Notes and Fair Value of Embedded Derivative (Details Narrative) - USD ($)																				1 Months Ended		12 Months Ended
	Oct. 16, 2013	Sep. 18, 2013	Sep. 04, 2013	Aug. 20, 2013	Aug. 14, 2013	Jul. 12, 2013	Jun. 27, 2013	Jun. 21, 2013	May 01, 2013	Apr. 26, 2013	Dec. 28, 2012	Oct. 25, 2012	Oct. 19, 2012	Sep. 27, 2012	Sep. 25, 2012	Sep. 19, 2012	Sep. 11, 2012	Aug. 27, 2012	Aug. 02, 2012	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2014	Oct. 31, 2013
Other noncash expense																							$ 157,000
Proceeds from convertible debt																							$ 2,968,500
Warrants outstanding																				4,265,262		4,158,092	4,265,262
Proceeds from related party debt																							$ 11,200
Issuance of common stock																						190,000
Chris French [Member]
Proceeds from convertible debt														$ 25,000
Conversion price percentage														50.00%
Percentage of beneficially own outstanding shares of common stock														4.99%
Third Asher Note [Member]
Debt instrument, interest rate, stated percentage									8.00%
Convertible promissory note principal amount									$ 203,500
Minimum [Member]
Warrants exercise price																				$ 5.63		$ 5.63	$ 5.63
Maximum [Member]
Warrants exercise price																				21.25		$ 21.25	$ 21.25
JMJ August 2012 Note [Member]
Debt conversion, converted instrument, amount																							$ 100,000
Debt conversion, converted instrument, shares issued																							24,744
Convertible promissory note principal amount																		$ 100,000
Proceeds from convertible debt																		$ 100,000
Fair value of debt																					$ 73,590
Non-cash income upon conversion																							$ 70,114
JMJ December 2012 Note [Member]
Long-term debt, gross										$ 125,000	$ 115,000
Convertible promissory note principal amount											100,000
Proceeds from convertible debt											100,000
Fair value of debt											$ 125,000
Payment of cash for exchange of debt										300,000
JMJ April 2013 Note [Member]
Debt conversion, converted instrument, amount					$ 145,833
Debt conversion, converted instrument, shares issued					71,438
Convertible promissory note principal amount					$ 583,333					800,000
Proceeds from convertible debt					$ 625,000					$ 720,000
Percentage of original debt issuance discount										10.00%
JMJ April 2013 Note [Member] \| Minimum [Member]
Debt instrument, convertible, conversion price					$ 1.89
JMJ April 2013 Note [Member] \| Maximum [Member]
Debt instrument, convertible, conversion price					$ 2.20
JMJ Financial [Member]
Debt instrument, interest rate, stated percentage			5.00%							5.00%
Long-term debt, gross			$ 583,333		$ 95,000		$ 195,000
Debt instrument, maturity date			Sep. 04, 2014							Apr. 26, 2014
Convertible promissory note principal amount	$ 1,167,000
Proceeds from convertible debt							$ 100,000			$ 425,000
Percentage of original debt issuance discount			10.00%							10.00%
Payment of cash for exchange of debt			$ 500,000
Debt instrument, convertible, terms of conversion feature			<p style="margin: 0pt"><font style="font: 10pt Times New Roman, Times, Serif">The convertible promissory note is convertible at any time, in whole or in part, at JMJ Financial’s option into shares of the Company’s Common Stock at the lesser of $2.65 or 70% of the average of the lowest two closing prices in the 20-day pricing period preceding a conversion . However, at no time will JMJ Financial be entitled to convert any portion of the note to the extent that after such conversion, JMJ Financial (together with its affiliates) would beneficially own more than 4.99% of the Company’s outstanding shares Common Stock as of such date. The Company agreed to reserve at least 2,000,000 shares of the Company’s Common Stock for conversion of the note.</font></p>							<p style="margin: 0pt"><font style="font: 10pt Times New Roman, Times, Serif">The convertible promissory note is convertible at any time, in whole or in part, at JMJ Financial’s option into shares of the Company’s Common Stock at the lesser of $8.75 or 70% of the average of the lowest two closing prices in the 20-day pricing period preceding a conversion . However, at no time will JMJ Financial be entitled to convert any portion of the note to the extent that after such conversion, JMJ Financial (together with its affiliates) would beneficially own more than 4.99% of the Company’s outstanding shares of Common Stock as of such date. The Company agreed to reserve at least 160,000 shares of its Common Stock for conversion of the note.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The convertible promissory note includes customary event of default provisions, and provides for a default rate of the lesser of 18 % or the maximum permitted by law. Upon the occurrence of an event of default, the lender may require the Company to pay in cash the “Mandatory Default Amount” which is defined in the note to mean the greater of (i) the outstanding principal amount of the note plus all interest, liquidated damages and other amounts owing under the note, divided by the conversion price on the date payment of such amount is demanded or paid in full, whichever is lower, multiplied by the volume-weighted-average price, or VWAP, on the date payment of such amount is demanded or paid in full, whichever has a higher VWAP, or (ii) 150% of the outstanding principal amount of the note plus 100% of all interest, liquidated damages and other amounts owing under the note. </p>
Percentage of public offering										125.00%
Proceeds from public offering										$ 10,000,000
Percentage of principal amount and accrued unpaid interest										125.00%
Sale of new convertible promissory note										$ 5,000,000
Number of restricted common stock issued			19,231
Number of restricted common stock issued for origination fee			$ 50,000
Consideration potential cash payment			220,000
Percentage of trading volume	10.00%
JMJ April 2013 Convertible Promissory Note [Member]
Proceeds from convertible debt					$ 100,000
JMJ September 2013 [Member]
Convertible promissory note principal amount			800,000
Proceeds from convertible debt			$ 720,000
Percentage of original debt issuance discount			10.00%
Accelerated Conversion And Note Temination Agreement With Jmj Financial [Member]
Debt conversion, converted instrument, amount	$ 1,167,000
Other noncash expense	922,000
Long-term debt, gross	$ 400,000
Accelerated Conversion And Note Temination Agreement With Jmj Financial [Member] \| Restricted Stock [Member]
Debt conversion, converted instrument, shares issued	783,333
Hanover Holdings Notes [Member]
Debt conversion, converted instrument, amount																							$ 365,000
Debt instrument, interest rate, stated percentage													12.00%
Debt conversion, converted instrument, shares issued																							97,333
Debt instrument, convertible, conversion price																				3.75			$ 3.75
Other noncash expense													$ 97,791			$ 97,791
Convertible promissory note principal amount													132,500			132,500
Proceeds from convertible debt													132,500			132,500
Fair value of debt													$ 363,000			$ 363,000
Conversion price percentage													65.00%
Percentage of beneficially own outstanding shares of common stock													4.99%
Interest expense debt																							$ 72,000
Magna Note [Member]
Debt conversion, converted instrument, amount																							$ 300,000
Debt instrument, interest rate, stated percentage												6.00%
Debt conversion, converted instrument, shares issued																							80,992
Other noncash expense																							$ 44,000
Debt instrument, maturity date												Oct. 17, 2013
Convertible promissory note principal amount												$ 340,523
Conversion price percentage												73.00%
Percentage of beneficially own outstanding shares of common stock												4.99%
Magna Note [Member] \| Third Parties [Member]
Acquisition of outstanding convertible notes																					400,076
Magna Note [Member] \| Other Third Parties [Member]
Acquisition of outstanding convertible notes																					$ 340,523
Magna Note [Member] \| Minimum [Member]
Debt instrument, convertible, conversion price																				3.21			$ 3.21
Magna Note [Member] \| Maximum [Member]
Debt instrument, convertible, conversion price																				$ 4.14			$ 4.14
Chris French [Member]
Debt conversion, converted instrument, amount																							$ 25,000
Debt instrument, interest rate, stated percentage														12.00%						562.50%			562.50%
Debt conversion, converted instrument, shares issued																							4,527
Other noncash expense																							$ 21,000
Convertible promissory note principal amount														$ 25,000
Accrued interest																				$ 633			$ 633
Issuance of warrants to acquire common stock																							2,263
Warrants expiration																							Oct. 26, 2015
Warrants exercise price																				$ 5.625			$ 5.625
Asher [Member]
Debt conversion, converted instrument, amount																							$ 153,500
Debt instrument, interest rate, stated percentage																	8.00%
Debt conversion, converted instrument, shares issued																							44,161
Debt instrument, maturity date																	Jun. 13, 2013
Convertible promissory note principal amount																	$ 103,500
Proceeds from convertible debt																	$ 100,000
Conversion price percentage																	61.00%
Percentage of beneficially own outstanding shares of common stock																	4.99%
Accrued interest																				$ 6,140			$ 6,140
Asher [Member] \| Minimum [Member]
Debt instrument, convertible, conversion price																				$ 3.43			$ 3.43
Asher [Member] \| Maximum [Member]
Debt instrument, convertible, conversion price																				$ 3.90			$ 3.90
Third Asher Note [Member]
Debt instrument, maturity date									Feb. 03, 2014
Proceeds from convertible debt									$ 200,000
Conversion price percentage									65.00%
Percentage of beneficially own outstanding shares of common stock									4.99%
Interest expense debt									$ 77,737
Repayment of debt									$ 281,237
Fourth Asher Note [Member]
Debt instrument, interest rate, stated percentage						8.00%
Convertible promissory note principal amount						$ 103,500
Proceeds from convertible debt						$ 100,000
Conversion price percentage						65.00%
Percentage of beneficially own outstanding shares of common stock						4.99%
Interest expense debt						$ 27,917
Repayment of debt																							$ 131,417
Yvonne Paterson [Member]
Debt conversion, converted instrument, amount																							$ 100,000
Debt instrument, interest rate, stated percentage															12.00%
Debt conversion, converted instrument, shares issued																							18,107
Other noncash expense																							$ 32,000
Convertible promissory note principal amount															$ 100,000
Proceeds from convertible debt															$ 100,000
Conversion price percentage															50.00%
Percentage of beneficially own outstanding shares of common stock															4.99%
Accrued interest																				$ 2,532			$ 2,532
Issuance of warrants to acquire common stock																							9,054
Warrants expiration																							Oct. 26, 2015
Warrants exercise price																				$ 5.625			$ 5.625
Dr. James Patton [Member]
Debt conversion, converted instrument, amount																							$ 66,667
Debt conversion, converted instrument, shares issued																							21,092
Debt instrument, maturity date																			Aug. 02, 2013
Convertible promissory note principal amount																			$ 66,667
Proceeds from convertible debt																			$ 50,000
Non-cash income upon conversion																							$ 94,000
Percentage of original debt issuance discount																			25.00%
Conversion price percentage																			50.00%
Percentage of beneficially own outstanding shares of common stock																			4.99%
Debt instrument, payment terms																			<p style="margin: 0pt">paid $0.75 for each $1.00 of principal amount.</p>
Common stock exercise price per share																			$ 0.15
Accretion of discount amounted																				$ 3,355			3,355
Warrants outstanding																						1,778
Redwood Management LLc [Member]
Debt conversion, converted instrument, amount																							$ 277,777
Debt instrument, interest rate, stated percentage								5.00%
Debt conversion, converted instrument, shares issued																							125,000
Debt instrument, convertible, conversion price																				$ 2.33			$ 2.33
Convertible promissory note principal amount								$ 277,777
Proceeds from convertible debt								$ 250,000
Percentage of original debt issuance discount								10.00%
Debt instrument, convertible, terms of conversion feature								<p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company agreed to reserve at least 2.5 times the number of shares of its Common Stock actually issuable upon full conversion of the Redwood Note, and not to take certain actions without Redwood’s consent and granted Redwood the right, at its election, to participate in future financings subject to certain limited exceptions. So long as the Company is not in default, and provided it has given 20 days prior written notice, it may prepay the Redwood Note in full at any time at a premium of 110% of the amount owed (which multiple increases 4 months after the issuance date). In addition, if the Company completes a financing of $7,000,000 or more, Redwood has the right, at its election, to require the Company to repay the Redwood Note in full on the closing date of such financing on the same payment terms as noted in the preceding sentence. The Redwood Note includes customary event of default provisions, and provide for a default rate of 14%.</p>
Conversion price percentage								70.00%
Percentage of beneficially own outstanding shares of common stock								4.99%
Accrued interest																				$ 4,300			$ 4,300
Percentage of placement agent fee received								8.00%
Conversion of lesser price per share								$ 6.25
Accredited Investor [Member]
Debt instrument, interest rate, stated percentage		20.00%
Debt instrument, maturity date		Feb. 21, 2014
Convertible promissory note principal amount				$ 108,000
Proceeds from convertible debt				$ 100,000
Accrued interest		$ 258,000
Warrants exercise price																				$ 10.625		$ 5.00	$ 10.625
Repayment of debt																							$ 278,000
Proceeds from related party debt		$ 150,000
Issuance of common stock		12,000																					62,981
Notes payable amount		$ 258,000
Junior Convertible Subordinated Convertible Notes [Member]
Minimum percentage of warrant received coverage																					23.00%
Maximum percentage of warrant received coverage																					75.00%
Exchange agreement warrants exercise price																					$ 18.75
Debt conversion, converted instrument, amount																							$ 11,765
Other noncash expense																							106,000
Long-term debt, gross																				$ 63,000			$ 63,000
Debt instrument, maturity date																							Oct. 22, 2011
December 2011 Note Financing [Member]
Debt conversion, converted instrument, amount																							$ 170,589
Issuance of notes																				$ 158,824			$ 158,824
Debt instrument, interest rate, stated percentage																				6.00%			6.00%
Third Magna Exchange Note [Member]
Debt conversion, converted instrument, amount																				$ 111,111			$ 111,111
Debt conversion, converted instrument, shares issued																				34,241
Convertible Notes Two [Member] \| Magna Note [Member]
Debt conversion, converted instrument, amount																							$ 341,000
Debt conversion, converted instrument, shares issued																							182,344
Other noncash expense																							$ 281,000
Convertible promissory note principal amount																					$ 740,599
Convertible Notes Two [Member] \| Magna Note [Member] \| Minimum [Member]
Debt instrument, interest rate, stated percentage																				316.00%			316.00%
Convertible Notes Two [Member] \| Magna Note [Member] \| Maximum [Member]
Debt instrument, interest rate, stated percentage																				349.00%			349.00%
Convertible Debt [Member] \| Magna Note [Member]
Convertible promissory note principal amount												$ 617,723
New Convertible Note [Member] \| Magna Note [Member]
Convertible promissory note principal amount												400,076
Remaining Convertible Note [Member] \| Magna Note [Member]
Convertible promissory note principal amount												$ 122,876

Notes Payable- Former Officer (Details Narrative) - USD ($)		1 Months Ended	12 Months Ended
	Feb. 04, 2014	Oct. 22, 2013	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2012
Repayments of related party debt			$ 64,926	$ 193,833
Moore Notes [Member]
Debt instrument, interest rate during period				12.00%
Process from notes payable				$ 600,000
Long-term debt, gross					$ 477,000
Repayments of notes payable		$ 100,000
Debt conversion, converted instrument, amount		$ 10,000,000		$ 163,132
Debt conversion, converted instrument, shares issued		40,783
Debt conversion, converted instrument, warrants or options issued		20,392
Debt conversion, converted instrument, warrants term				5 years
Debt conversion converted instrument warrants exercise price				$ 5.00
Notes payable, current				$ 11,200
Repayments of debt				193,833
Notes payable and interest payable current				163,132
Repayments of related party debt	$ 168,280
Interest expense, debt			$ 7,200	$ 31,600

Common Stock Purchase Warrants and Warrant Liability (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Warrants outstanding	4,158,092	4,265,262
Number of warrants	4,200,000	4,300,000
Fair value of warrant liability	$ 32,000	$ 600,000
Embedded derivative liability outstanding	4,200,000	4,300,000
Weighted average anti dilutive warrants	60,000	203,000
Gain (Loss) on Change in Fair Value of Common Stock Warrant Liability and Embedded Derivative Liability	$ 619,089	$ (1,504,465)
Anti dillution provision	37,200
Proceeds from issuance of warrants	$ 250	$ 94,444
Common stock issued during period	2,110	6,334
Anti dilution provision warrant	60,069
Anti dilution warrants expired	459,744	500
Anti-dilution provisions warrants exercise price	$ 25.00
Anti dilution provision warrants period	5 years
Warrants exercise price	$ 7.71	$ 9.24
Anti-dilution provisions additional warrants issuable	32,000
Fair value of embedded derivative liability	$ 0	$ 0
Tonaquint [Member]
Common stock issued during period		484,876
Cashless Exercises Warrants		189,415
Accredited Investor [Member]
Exercise price per share	$ 5.00	$ 10.625
Exercise of warrants	50	8,889
Common Stock Warrant Liability [Member]
Warrants outstanding	123,000	600,000
Equity Warrants [Member]
Warrants outstanding	4,000,000	3,700,000
Liability Warrant [Member]
Warrants outstanding	4,200,000	4,300,000
Embedded derivative liability outstanding	123,000	565,000
Liability Warrants One [Member]
Warrants outstanding		287,000
Exchange Warrants [Member]
Warrants outstanding	278,000
Warrant Liability [Member]
Fair value of warrant liability		$ 32,091
Warrant Equity [Member]
Fair value of warrant liability	$ 646,734
Warrants [Member]
Fair value of embedded derivative liability	32,000	647,000
Embedded Derivatives [Member]
Fair value of embedded derivative liability	$ 0	$ 0
Minimum [Member]
Exercise price per share	$ 5.63	$ 5.63
Minimum [Member] \| Warrants With Anti Dilution Provisions [Member]
Anti-dilution provisions warrants exercise price	$ 6.50
Probability of exercise of additional warrants at exercise price one	40.00%
Probability of exercise of additional warrants at exercise price two	50.00%
Maximum [Member]
Exercise price per share	$ 21.25	21.25
Maximum [Member] \| Warrants With Anti Dilution Provisions [Member]
Anti-dilution provisions warrants exercise price	$ 7.79
Probability of exercise of additional warrants at exercise price one	50.00%
Probability of exercise of additional warrants at exercise price two	60.00%
Warrants [Member] \| Minimum [Member]
Exercise price per share	$ 2.76	2.76
Warrants [Member] \| Maximum [Member]
Exercise price per share	$ 21.25	$ 21.25
Common Stock [Member]
Warrants outstanding	4,265,262	4,158,092
Common stock issued during period	4,692,000	6,612,500

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Outstanding (Details) - $ / shares	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Class of Warrant or Right, Outstanding	4,158,092	4,265,262
Consultant [Member] \| Common Stock Purchase Warrant [Member]
Expiration Date		September 2015
Exchange Warrants Nonexercisable [Member] \| July 2012 Exchanges [Member]
Exercise Price		$ 18.75
Class of Warrant or Right, Outstanding		278,329
Expiration Date		October 2014
Common Stock Purchase Warrant [Member] \| May 2011 Convertible Debt Financing [Member]
Exercise Price	$ 18.75	$ 18.75
Class of Warrant or Right, Outstanding	28,632	28,632
Expiration Date	May 2015	May 2015
Common Stock Purchase Warrant [Member] \| Oct 2011 Convertible Debt Financings [Member]
Exercise Price	$ 18.75	$ 18.75
Class of Warrant or Right, Outstanding	10,059	11,628
Expiration Date	October 2015
Common Stock Purchase Warrant [Member] \| Oct 2011 Convertible Debt Financings [Member] \| Minimum [Member]
Expiration Date		October 2014
Common Stock Purchase Warrant [Member] \| Oct 2011 Convertible Debt Financings [Member] \| Maximum [Member]
Expiration Date		October 2015
Common Stock Purchase Warrant [Member] \| December 2011 Convertible Debt Financing [Member]
Exercise Price	$ 18.75	$ 18.75
Class of Warrant or Right, Outstanding	17,706	17,706
Common Stock Purchase Warrant [Member] \| December 2011 Convertible Debt Financing [Member] \| Minimum [Member]
Expiration Date	May 2015	May 2015
Common Stock Purchase Warrant [Member] \| December 2011 Convertible Debt Financing [Member] \| Maximum [Member]
Expiration Date	January 2016	January 2016
Common Stock Purchase Warrant [Member] \| May 2012 Convertible Debt Financing [Member]
Exercise Price	$ 18.75	$ 18.75
Class of Warrant or Right, Outstanding	13,333	13,333
Expiration Date	May 2017	May 2017
Common Stock Purchase Warrant [Member] \| Bridge Notes [Member]
Exercise price minimum	$ 7.77	$ 9.24
Exercise price maximum	$ 21.25	$ 21.25
Class of Warrant or Right, Outstanding	112,460	293,115
Common Stock Purchase Warrant [Member] \| Bridge Notes [Member] \| Minimum [Member]
Expiration Date	December 2014	December 2013
Common Stock Purchase Warrant [Member] \| Bridge Notes [Member] \| Maximum [Member]
Expiration Date	April 2015	April 2015
Common Stock Purchase Warrant [Member] \| Vendor & Other [Member]
Exercise Price	$ 18.75	$ 18.75
Class of Warrant or Right, Outstanding	376	376
Expiration Date	N/A	N/A
Common Stock Purchase Warrant [Member] \| Placement Agent Convertible Debt Financing [Member]
Exercise price minimum	$ 10.625	$ 10.625
Exercise price maximum	$ 18.75	$ 18.75
Class of Warrant or Right, Outstanding	7,855	29,883
Common Stock Purchase Warrant [Member] \| Placement Agent Convertible Debt Financing [Member] \| Minimum [Member]
Expiration Date	January 2015	May 2014
Common Stock Purchase Warrant [Member] \| Placement Agent Convertible Debt Financing [Member] \| Maximum [Member]
Expiration Date	May 2017	May 2017
Common Stock Purchase Warrant [Member] \| Former Officer [Member]
Exercise Price	$ 5.00	$ 5.00
Class of Warrant or Right, Outstanding	20,392	20,392
Expiration Date	October 2018	October 2018
Common Stock Purchase Warrant [Member] \| Consultant [Member]
Exercise Price	$ 4.90	$ 4.90
Class of Warrant or Right, Outstanding	30,154	30,154
Expiration Date	September 2015
Common Stock Purchase Warrant [Member] \| Stock Purchase Agreement [Member]
Exercise price minimum	$ 2.76	$ 2.76
Exercise price maximum	$ 5.52	$ 4.375
Class of Warrant or Right, Outstanding	277,055	23,994
Expiration Date	March 2024
Common Stock Purchase Warrant [Member] \| Stock Purchase Agreement [Member] \| Minimum [Member]
Expiration Date	December 2015	December 2015
Common Stock Purchase Warrant [Member] \| Stock Purchase Agreement [Member] \| Maximum [Member]
Expiration Date		August 2016
Common Stock Purchase Warrant [Member] \| August and September 2012 Convertible Promissory Notes [Member]
Exercise price minimum		$ 5.625
Exercise price maximum		$ 18.75
Class of Warrant or Right, Outstanding		13,095
Common Stock Purchase Warrant [Member] \| Advaxis Public Offering [Member]
Exercise Price	$ 5.00	$ 5.00
Class of Warrant or Right, Outstanding	3,306,200	3,306,250
Expiration Date		October 2018
Common Stock Purchase Warrant [Member] \| Representative Advaxis Public Offering [Member]
Exercise Price		$ 5.00
Exercise price minimum	$ 3.75
Exercise price maximum	$ 5.00
Class of Warrant or Right, Outstanding	320,775	198,375
Expiration Date		October 2018
Common Stock Purchase Warrant [Member] \| August and September 2012 Convertible Promissory Notes [Member] \| Minimum [Member]
Expiration Date		October 2015
Common Stock Purchase Warrant [Member] \| August and September 2012 Convertible Promissory Notes [Member] \| Maximum [Member]
Expiration Date		August 2017
Common Stock Purchase Warrant [Member] \| August - September 2012 Convertible Promissory Notes [Member]
Exercise price minimum	$ 5.625
Exercise price maximum	$ 18.75
Class of Warrant or Right, Outstanding	13,095
Common Stock Purchase Warrant [Member] \| August - September 2012 Convertible Promissory Notes [Member] \| Minimum [Member]
Expiration Date	October 2015
Common Stock Purchase Warrant [Member] \| August - September 2012 Convertible Promissory Notes [Member] \| Maximum [Member]
Expiration Date	August 2017
Common Stock Warrant Liability [Member] \| Advaxis Public Offering [Member]
Expiration Date	October 2018
Common Stock Warrant Liability [Member] \| Representative Advaxis Public Offering [Member] \| Minimum [Member]
Expiration Date	October 2018
Common Stock Warrant Liability [Member] \| Representative Advaxis Public Offering [Member] \| Maximum [Member]
Expiration Date	March 2019

Stock Options - Schedule of Share-based Compensation (Details) - USD ($)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Options, Outstanding, Beginning balance	467,923	358,459
Number of Options, Granted	36,000	134,600
Number of Options, Cancelled or Expired	(35,955)	(25,136)
Number of Options, Outstanding, Ending Balance	467,968	467,923
Number of Options, Vested and Exercisable	406,017
Weighted-Average Exercise Price, Outstanding, Beginning	$ 15.86	$ 20.00
Weighted-Average Exercise Price, Granted	4.02	9.38
Weighted-Average Exercise Price, Cancelled or Expired	8.57	12.50
Weighted-Average Exercise Price, Outstanding, Ending	15.51	$ 15.86
Weighted-Average Exercise Price, Vested and Exercisable	$ 15.89
Weighted Average Remaining Contractual Life In Years, Outstanding, Beginning	7 years 3 months 11 days	8 years
Weighted Average Remaining Contractual Life In Years, Granted	9 years 1 month 28 days	9 years 6 months
Weighted Average Remaining Contractual Life In Years, Outstanding, Ending	6 years 4 months 2 days	7 years 3 months 11 days
Weighted Average Remaining Contractual Life In Years, Vested and Exercisable	5 years 9 months 26 days
Aggregate Intrinsic Value, Outstanding, Beginning
Aggragate Intrinsic Value, Granted
Aggregate Intrinsic Value, Cancelled or Expired
Aggregate Intrinsic Value, Outstanding, Ending
Aggregate Intrinsic Value, Vested and Exercisable

Commitments and Contingencies (Details Narrative)							1 Months Ended						12 Months Ended
Commitments and Contingencies (Details Narrative)	Dec. 27, 2014 USD ($)	Nov. 15, 2013 USD ($)	Sep. 17, 2013 $ / shares shares	Aug. 19, 2013 USD ($) $ / shares shares	Aug. 19, 2013 USD ($) $ / shares shares	Jun. 19, 2009 USD ($)	Apr. 30, 2014 USD ($)	Mar. 31, 2014 USD ($) shares	Jan. 31, 2014 USD ($)	Dec. 31, 2013 USD ($) shares	Oct. 31, 2013 USD ($) shares	Apr. 30, 2011 USD ($) ft²	Oct. 31, 2014 USD ($) shares	Oct. 29, 2014 USD ($)	Oct. 31, 2013 USD ($)	Mar. 24, 2014 USD ($)	Dec. 12, 2013 shares	Sep. 27, 2013 shares	Mar. 22, 2013 USD ($) shares
Stock compensation expense \| $													$ 128,241
Share-based compensation, common stock, shares													40,320
Share-based compensation, shares on net basis after employee payroll taxes													31,026
Issuance of common stock													190,000
Number of stock forfeited													80,000
Settlement amount \| $											$ 150,000
Shares issued													30,000,000					158,385
Proceeds from net operating losses \| $									$ 625,563
Area of lease \| ft²												10,000
Initial security deposit \| $												$ 8,000
Security deposit \| $												$ 54,000
Sublease agreement termination period												2015-11
Rent expense \| $													$ 330,000		$ 229,416
Taxes receivable \| $													1,731,317
Termination agreement amount \| $		$ 484,710
Officer And Laboratory Lease [Member]
Lease costs \| $												$ 338,000
Officer And Laboratory Lease [Member] \| November 2015 [Member]
Lease costs \| $													1,020,000
Maxim Group LLC [Member]
Debt conversion, warrants exercise price \| $ / shares				$ 4.90	$ 4.90
Mr Moore [Member]
Stock compensation expense \| $													$ 340,039
Share-based compensation, common stock, shares													84,377
Numoda Corporation [Member]
Amount owed by numoda \| $						$ 540,000
Minimum [Member]
Utility costs \| $							$ 7,200
Maximum [Member]
Utility costs \| $												$ 10,700
Restricted Stock Units (RSUs) [Member] \| Mr Moore [Member]
Stock compensation expense \| $													$ 46,099
Shares granted, RSUs										37,500
Shares granted vested over year										3 years
Percentage of stock units vested by third anniversary of grant date										100.00%
RSUs vesting, shares										10,976
Award vesting period										3 years
2011 Omnibus Incentive Plan [Member] \| Minimum [Member]
Vesting issuance													520,000
Shares issued													520,000
2011 Omnibus Incentive Plan [Member] \| Maximum [Member]
Vesting issuance													2,120,000
Shares issued													2,120,000
Common Stock [Member]
Conversion debt into shares								3,333			13,500		34,752
Conversion of debt into shares, amount \| $								$ 10,000			$ 54,000		$ 182,919
Shares issued													25,000,000
Promissory Note One [Member]
Conversion debt into shares													21,091
Conversion of debt into shares, amount \| $													$ 66,500
Daniel J. O' Connor [Member]
Issuance of common stock													72,676
Number of stock shares issued during period amount \| $													$ 313,419
Executive Officers [Member] \| Stock Bonus Award [Member]
Stock compensation expense \| $													$ 879,883
Total fair value of bonus shares issued \| $										$ 129,000
Bonus shares issued										31,846			218,333
Bonus shares issued on net basis after employee payroll taxes										21,389			133,903
Shares of common stock granted													525,000
Shares of common stock granted, vested immediately													105,000
Number of common shares vested for employee payroll taxes													63,949
Shares vested, total fair value \| $													$ 423,150
Executive Officers [Member] \| Restricted Stock Units (RSUs) [Member]
Total fair value of bonus shares issued \| $										$ 336
Shares granted, RSUs										420,000
Percentage of stock units vested by third anniversary of grant date										100.00%
Non Executive Employees [Member]
Number of stock forfeited													2,316
Non Executive Employees [Member] \| Stock Bonus Award [Member]
Shares vested, total fair value \| $										$ 5,025
RSUs vesting, shares on net basis after employee payroll taxes										3,685
Non Executive Employees [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based compensation, common stock, shares										25,124
Shares vested, total fair value \| $										$ 20,250
Percentage of stock units vested by third anniversary of grant date										100.00%
Grant date fair value \| $										$ 101,250
RSUs vesting, shares										20,099
Shares granted, aggregate value, RSUs \| $										$ 81,250
Non Executive Employees [Member]
Shares granted, RSUs			25,582
Non Executive Employees [Member] \| Stock Bonus Award [Member]
Stock compensation expense \| $													$ 45,719
Bonus shares issued																	11,362
Bonus shares issued on net basis after employee payroll taxes																	8,758
Non Employee Director [Member] \| Restricted Stock Units (RSUs) [Member]
Shares granted, RSUs										50,000
Shares granted vested over year										3 years
Percentage of stock units vested by third anniversary of grant date										100.00%
Award vesting period										3 years
Iliad Research and Trading, L.P. [Member]
Damages on claim plus interest, attorneys' fees and costs \| $																$ 300,000
Brio Capital LP [Member]
Settlement amount \| $														$ 205,000
Damages on claim plus interest, attorneys' fees and costs \| $																			$ 500,000
Shares issued																			21,742
Debt conversion, warrants exercise price \| $ / shares			$ 4.90
Maxim Group LLC [Member]
Shares granted, RSUs					30,154
Settlement amount \| $	$ 285,000
Aggregate payment to claimant \| $					$ 589,000
Mr Moore [Member] \| Consulting Agreement [Member]
Shares granted, RSUs				37,500
Shares granted vested over year				3 years
RSUs vesting, shares				10,976
Award vesting period				3 years
Aggregate payment to claimant \| $				$ 350,000
Consulting agreement termination date				Aug. 18, 2014

Income Taxes - Reconciliation Expected Tax (Expense) Benefit Based on Statutory Rate with Actual Tax Expense Benefit (Details)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Income Tax Disclosure [Abstract]
US Federal statutory rate	34.00%	34.00%
State income tax, net of federal benefit	5.90%	5.90%
Deferred tax true-up - permanent differences	0.20%	(9.80%)
Non-deductible loss on note retirement	0.00%	(9.40%)
Deferred tax adjustment	(13.30%)	(0.70%)
Change in valuation allowance	(25.30%)	(19.00%)
Income tax benefit from sale of New Jersey NOL carryovers	12.50%	3.50%
Other permanent differences	(1.50%)	(1.00%)
Income tax (provision) benefit	12.50%	3.50%

Shareholders' Equity (Details Narrative) - USD ($)							3 Months Ended	12 Months Ended
Shareholders' Equity (Details Narrative) - USD ($)	Jul. 11, 2014	May 15, 2014	Mar. 19, 2014	Dec. 09, 2013	Sep. 18, 2013	Jul. 19, 2010	Apr. 30, 2014	Oct. 31, 2014	Oct. 31, 2013	Oct. 12, 2014	Sep. 27, 2013	Sep. 26, 2013	Oct. 26, 2012
Issuance of shares								30,000,000			158,385
Common stock, shares authorized								45,000,000	45,000,000
Percentage of common stock sale price								90.00%
Non cash expense									$ 157,000
Issuance of common stock								190,000
Net proceeds of issuance of Common Stock								$ 14,580,808	27,438,931
Issuance of shares exchange								7,080
Value of shares exchange								$ 34,126
Ratio of reverse stock split	<p style="margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">1-for-125</font></p>
Stock price per share	$ 0.001
Common stock shares issued during period for services								200,000
Value of shares issued for services								$ 756,000
Common stock value									$ 100,000			$ 10,633,584
Percentage of redemption on preferred stock									10.00%
Issuance of stock								33,750
Fair value of stock								221,400
Accrued dividends payable								2,877,570
Preferred stock liquidation preference
Promissory note bearing interest rate								2.00%
Series B Preferred Stock [Member]
Common stock shares issued during period for services						7,500,000
Accrued dividends payable									555,000	$ 0
Accrued interest									$ 149,562	$ 0
Global BioPharma Inc [Member]
Issuance of common stock				108,724
Stock price per share				$ 3.68
Equity investment amount				$ 400,000
Number of warrants received				100,000
Warrants exercise price				$ 5.52
Warrants expiration date				Dec. 31, 2018
Payment to offset development costs				$ 2,250,000
Aratana Therapeutics [Member]
Issuance of common stock			306,122
Stock price per share			$ 4.90
Payment for license amount			$ 1,000,000
Payment for achievement of certain milestones								$ 36,500,000
Cumulative sales								15,000,000
Issuance of warrants to purchase of common stock			153,061
Common stock exercise price			$ 4.90
Proceeds from issuance of common stock and warrants			$ 1,500,000
Aratana Therapeutics and Global Biopharma Inc., [Member]
Net proceeds of issuance of Common Stock								$ 2,000,000
License revenue							$ 1,000,000
Accredited Investor [Member]
Issuance of common stock					12,000				62,981
Net proceeds of issuance of Common Stock									$ 177,250
Yenson Co. Ltd [Member]
Common stock shares issued during period for services		45,323
Hanover Purchase Agreement [Member]
Issuance of shares								28,000
Common Stock Purchase Agreement [Member]
Issuance of shares													10,000,000
Equity Enhancement Program [Member]
Issuance of common stock									359,224
Net proceeds of issuance of Common Stock									$ 2,964,140
Common Stock [Member]
Issuance of shares								25,000,000
Preferred Stock [Member]
Issuance of shares								5,000,000
Series B Preferred Stock [Member]
Preferred stock price per share						$ 10,000
2011 Omnibus Incentive Plan [Member] \| Minimum [Member]
Issuance of shares								520,000
Common stock, shares authorized								25,000,000
2011 Omnibus Incentive Plan [Member] \| Maximum [Member]
Issuance of shares								2,120,000
Common stock, shares authorized								45,000,000

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Cash equivalents
Concentration risk credit risk financial instrument maximum exposure	$ 17,600,000
Intangible assets estimated useful lives	20 years
Adveristing costs
Minimum [Member]
Research and development contracts, amortization period	6 months
Property and equipment estimated useful lives	3 years
Maximum [Member]
Research and development contracts, amortization period	5 years
Property and equipment estimated useful lives	5 years

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Oct. 31, 2014	Oct. 31, 2013
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 27,611	$ 19,299

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Oct. 31, 2014	Oct. 31, 2013
Property, Plant and Equipment [Abstract]
Laboratory Equipment	$ 333,727	$ 309,132
Accumulated Depreciation	(256,358)	(228,747)
Net Property and Equipment	$ 77,369	$ 80,385

Intangible Assets - Summary of Intangible Assets (Details) - USD ($)	Oct. 31, 2014	Oct. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
License	$ 651,992	$ 651,992
Patents	3,111,624	2,696,543
Total intangibles	3,763,616	3,348,535
Accumulated Amortization	(995,671)	(819,984)
Intangible Assets	$ 2,767,945	$ 2,528,551

Intangible Assets - Schedule of Amortization Expense (Details)	Oct. 31, 2014 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2015	$ 188,000
2016	188,000
2017	188,000
2018	188,000
2019	$ 188,000

Balance Sheets (Parenthetical) - USD ($)	Oct. 31, 2014	Oct. 31, 2013
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Preferred stock, liquidation preference value
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	19,630,139	13,719,861
Common stock, shares outstanding	19,630,139	13,719,861

Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details) - shares	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Number of potential shares of Common Stock that have been excluded from diluted net loss per share	4,629,414	4,736,539
Warrants [Member]
Number of potential shares of Common Stock that have been excluded from diluted net loss per share	4,158,092	4,265,262
Stock Options [Member]
Number of potential shares of Common Stock that have been excluded from diluted net loss per share	467,968	467,923
Convertible Debt [Member]
Number of potential shares of Common Stock that have been excluded from diluted net loss per share	3,354	3,354

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
Intangible Assets (Details Narrative) - USD ($)	Oct. 31, 2014	Oct. 31, 2013
Amortization expense of intangibles	$ 175,686	$ 159,337
Minimum [Member]
Finite lived patents expirations	2015
Maximum [Member]
Finite lived patents expirations	2028

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Oct. 31, 2014	Oct. 31, 2013
Payables and Accruals [Abstract]
Salaries and Other Compensation	$ 890,069	$ 752,248
Vendors	121,200
Professional Fees	208,000	17,000
Withholding Taxes Payable	22,527
Share Purchase		100,012
Accrued Liabilities, Current	$ 1,241,796	$ 869,260

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details)	12 Months Ended
	Oct. 31, 2014 USD ($) $ / shares shares
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Number of Warrants, Outstanding, Beginning balance \| shares	4,265,262
Number of Warrants, Issued \| shares	412,693
Number of Warrants, Exercised \| shares	(50)
Number of Warrants, Expired \| shares	(519,813)
Number of Warrants, Outstanding, Ending balance \| shares	4,158,092
Weighted-Average Exercise Price, Outstanding, Beginning \| $ / shares	$ 6.71
Weighted-Average Exercise Price, Issued \| $ / shares	4.97
Weighted-Average Exercise Price, Exercised \| $ / shares	5.00
Weighted-Average Exercise Price, Expired \| $ / shares	15.01
Weighted-Average Exercise Price, Outstanding, Ending \| $ / shares	$ 5.42
Weighted Average Remaining Contractual Life In Years, Beginning	4 years 2 months 19 days
Weighted Average Remaining Contractual Life In Years, Ending	3 years 11 months 9 days
Aggregate Intrinsic Value, Beginning \| $	$ 22,208
Aggregate Intrinsic Value, Ending \| $	$ 9,518

Stock Options (Details Narrative) - USD ($)	12 Months Ended
Stock Options (Details Narrative) - USD ($)	Oct. 31, 2014	Oct. 31, 2013	Dec. 31, 2011
Total compensation cost	$ 926,000	$ 3,500,000
Fair value of option granted	144,640	1,215,875
Share-based compensation, non-vested awards, total compensation cost not yet recognized, stock options	$ 807,000
Non-vested stock option awards remaining average vesting period	80 days
Proceeds from Stock Plans	$ 6,251	$ 28,040
Common stock issued during period	2,110	6,334
2011 Employee Stock Purchase Plan [Member]
Percentage of discount on stock purchase plan	15.00%
Common stock are reserved for issuance	29,890		40,000
Research and Development Expenses [Member]
Total compensation cost	$ 357,000	$ 1,200,000
General and Administrative Expenses [Member]
Total compensation cost	$ 569,000	$ 2,300,000

Stock Option - Summary of Stock Option Plans using Black Scholes Pricing Model (Details)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Expected volatility		138.05%
Expected Life	5 years	5 years 6 months
Dividend yield	0.00%	0.00%
Risk-free interest rate		2.04%
Forfeiture Rate	4.40%	4.40%
Minimum [Member]
Expected volatility	151.38%
Risk-free interest rate	1.39%
Maximum [Member]
Expected volatility	171.12%
Risk-free interest rate	1.72%

Commitments and Contingencies - Schedule of Allocation of Base Salary (Details) - USD ($)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Annual amount to be purchased	$ 4,428,712	$ 4,545,992
Cumulative net purchase	14,580,808	$ 27,438,931
Daniel J. O' Connor [Member]
Annual amount to be purchased	81,250
Cumulative gross purchase	$ 68,750
Cumulative shares gross purchase	21,687
Cumulative net purchase	$ 50,891
Cumulative shares net purchase	15,950
David J. Mauro [Member]
Annual amount to be purchased	$ 15,750
Cumulative gross purchase	$ 606
Cumulative shares gross purchase	190
Cumulative net purchase	$ 527
Cumulative shares net purchase	165
Gregory T. Mayes [Member]
Annual amount to be purchased	$ 19,875
Cumulative gross purchase	$ 16,818
Cumulative shares gross purchase	5,305
Cumulative net purchase	$ 13,801
Cumulative shares net purchase	4,333
Robert G. Petit [Member]
Annual amount to be purchased	$ 24,225
Cumulative gross purchase	$ 20,498
Cumulative shares gross purchase	6,466
Cumulative net purchase	$ 16,363
Cumulative shares net purchase	5,159
Sara M. Bonstein [Member]
Annual amount to be purchased	$ 16,875
Cumulative gross purchase	$ 10,384
Cumulative shares gross purchase	3,355
Cumulative net purchase	$ 8,038
Cumulative shares net purchase	2,585
Chris L. French [Member]
Annual amount to be purchased	$ 10,750
Cumulative gross purchase	$ 8,837
Cumulative shares gross purchase	2,785
Cumulative net purchase	$ 7,475
Cumulative shares net purchase	2,352

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
Income Taxes (Details Narrative) - USD ($)	Oct. 31, 2014	Oct. 31, 2013
Income Tax Disclosure [Abstract]
U.S. federal net operating loss carryovers (NOLs)	$ 75,320,000	$ 58,447,000
New Jersey State Net Operating Loss carryovers	$ 18,123,000	17,563,000
Operating loss expiration year	2023
Change in valuation allowance	$ 4,770,000	3,928,000
Interest or penalties on unpaid tax	0	0
Liability for unrecognized tax benefits	$ 0	$ 0

Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Details) - USD ($)	Oct. 31, 2014	Oct. 31, 2013
Income Tax Disclosure [Abstract]
Net operating loss carryovers	$ 26,685,000	$ 21,994,270
Stock-based compensation	3,467,000	3,772,857
Other deferred tax assets	2,094,000	1,603,056
Total deferred tax assets	32,246,000	27,370,183
Valuation allowance	(31,112,000)	(26,342,495)
Deferred tax asset, net of valuation allowance	1,134,000	1,027,688
Other deferred tax liabilities	(1,134,000)	(1,027,688)
Total deferred tax liabilities	(1,134,000)	(1,027,688)
Net deferred tax asset (liability)

Fair Value - Fair Value, Liabilities Measured on Recurring Basis (Details) - USD ($)	Oct. 31, 2014	Oct. 31, 2013
Common stock warrant liability, warrants exercisable	$ 32,091	$ 646,734
Fair Value, Inputs, Level 1 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 3 [Member]
Common stock warrant liability, warrants exercisable	$ 32,091	$ 646,734

Fair Value - Fair Value, Liabilities Measured on Recurring Basis (Details) (Parenthetical) - $ / shares	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Warrants exercisable period	<p style="margin: 0pt"></p> <p style="margin: 0pt">October 2014 through August 2017</p>	<p style="margin: 0pt"></p> <p style="margin: 0pt">October 2013 through August 2017</p>
Minimum [Member]
Exercise Price	$ 5.63	$ 5.63
Maximum [Member]
Exercise Price	$ 21.25	$ 21.25

Fair Value - Instruments Classified In Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - USD ($)	12 Months Ended
	Oct. 31, 2014	Oct. 31, 2013
Issuance of Common Stock warrants	$ 33,750
Common Stock Warrant Liability [Member]
Beginning balance	646,734	$ 434,136
Issuance of Common Stock warrants		1,460,867
Exercises and exchanges of warrants		(1,026,131)
Issuance of additional warrants due to anti-dilution provisions	4,446	123,744
Change in fair value	(619,089)	(345,882)
Ending Balance	$ 32,091	$ 646,734

Subsequent Events (Details Narrative) - USD ($)								12 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Dec. 31, 2014	Dec. 22, 2014	Dec. 19, 2014	Dec. 05, 2014	Nov. 28, 2014	Nov. 25, 2014	Nov. 10, 2014	Oct. 31, 2014	Oct. 31, 2013
Common stock issued for services								200,000
Number of shares issued as per employment agreements								190,000
Stock options to an advisor pursuant to a consulting agreement								36,000	134,600
During period shares issued								2,110	6,334
Subsequent Event [Member]
Stock options to an advisor pursuant to a consulting agreement						20,000
Number of shares priced registered direct offering common stock			3,940,801
Proceeds from registered direct offering		$ 16,700,000
Subsequent Event [Member] \| Executive Officers [Member]
During period shares issued	1,504
Accredited Investor [Member] \| Subsequent Event [Member]
Common stock issued for services				30,000			40,000
Executive Officers [Member] \| Subsequent Event [Member]
Number of shares issued as per employment agreements					3,868